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Abstract

In emerging domains, such as precision oncology, knowledge extracted from explicit
assertions may be insufficient to identify relationships of interest. One solution to this
problem involves drawing inference on the basis of similarity. Computational methods
have been developed to estimate the semantic similarity and relatedness between terms and
relationships that are distributed across corpora of literature such as Medline abstracts and
other forms of human readable text. Most research on distributional similarity has focused
on the notion of attributional similarity, which estimates the similarity between entities
based on the contexts in which they occur across a large corpus. A relatively underresearched area concerns relational similarity, in which the similarity between pairs of
entities is estimated from the contexts in which these entity pairs occur together. While it
seems intuitive that models capturing the structure of the relationships between entities
might mediate the identification of biologically important relationships, there is to date no
comparison of the relative utility of attributional and relational models for this purpose.
In this research, I compare the performance of a range of relational and attributional
similarity methods, on the task of identifying drugs that may be therapeutically useful in
the context of particular aberrant genes, as identified by a team of human experts. My
hypothesis is that relational similarity will be of greater utility than attributional similarity
iv

as a means to identify biological relationships that may provide answers to clinical
questions, (such as “which drugs INHIBIT gene x”?) in the context of rapidly evolving
domains.
My results show that models based on relational similarity outperformed models based on
attributional similarity on this task. As the methods explained in this research can be
applied to identify any sort of relationship for which cue pairs exist, my results suggest that
relational similarity may be a suitable approach to apply to other biomedical problems.
Furthermore, I found models based on neural word embeddings (NWE) to be particularly
useful for this task, given their higher performance than Random Indexing-based models,
and significantly less computational effort needed to create them. NWE methods (such as
those produced by the popular word2vec tool) are a relatively recent development in the
domain of distributional semantics, and are considered by many as the state-of-the-art
when it comes to semantic language modeling. However, their application in identifying
biologically important relationships from Medline in general, and specifically, in the
domain of precision oncology has not been well studied.
The results of this research can guide the design and implementation of biomedical
question answering and other relationship extraction applications for precision medicine,
precision oncology and other similar domains, where there is rapid emergence of novel
knowledge. The methods developed and evaluated in this project can help NLP
applications provide more accurate results by leveraging corpus based methods that are by
design scalable and robust.
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Chapter 1: Introduction

Background
Biomedical literature is growing rapidly. In 2015 alone, more than 870,000 publications
were added to, and indexed in Medline (Figure 1).(“MEDLINE Citation Counts by Year
of Publication,” n.d.). Clinicians and other researchers that look for specific answers to

Figure 1. Medline citations by year.

their questions may be faced with overwhelmingly large sets of documents returned by
information retrieval systems, such as PubMed. System that extract specific relationships
1

from text (such as Question Answering - QA systems) rather than documents that may
contain the relationships of interest have the potential to address this problem. However,
the majority of those systems rely on well-established knowledge resources (such as known
relations between concepts (At, 1989)) to extract information from the biomedical
literature. (Athenikos & Han, 2010) Rapidly evolving domains (such as precision
oncology) pose unique challenges to QA and other relationship extraction systems. Due to
the rapid emergence of new knowledge in these domains (such as discovery of new drugs
or new molecular targets), the resources found in the clinical literature are scarce by
definition, and systems such as SemRep, a Natural Language Processing (NLP) system for
biomedical literature, which are optimized for precision, and rely solely on knowledge
extracted from explicit assertions (such as “rapamycin inhibits mtor”) may miss
relationships of interest. (Fathiamini et al., 2016)
It has been argued that methods that infer relationships between biomedical concepts by
examining the ways in which they are distributed across large text corpora, present a robust
and desirable alternative (Percha & Altman, 2015). In these approaches, generally known
as methods of “distributional semantics”, similar representations are generated for terms
that occur in similar contexts in the literature, (Trevor Cohen & Widdows, 2009) and the
similarity between concepts of interest can be measured.
Most research on distributional similarity has focused on the notion of attributional
similarity, which estimates the similarity between entities (such as two drugs). However,
an important component of QA involves identifying relationships between concepts.
2

Therefore, relational similarity, the estimation of the similarity between pairs of entities
(such as two drug-gene pairs) based on the nature of the relationship between them is
important. Relational similarity is estimated from the contexts in which these entity pairs
occur together, and may help identify interesting relationships between biomedical
concepts. However, within biomedicine scant research exists on this topic. Methods for
estimation of relational similarity have seldom been evaluated, and little is known about
how these methods might be leveraged for QA purposes in emerging domains.
Hypothesis and Specific Aims
The dissertation explores the utility of a scalable corpus-based approach to estimate the
relational similarity between pairs of concepts extracted from Medline abstracts. My
hypothesis is that relational similarity will be of greater utility than attributional similarity
as a means to identify biological relationships that may provide answers to clinical
questions, (such as “which drugs INHIBIT gene x”?) in the context of rapidly evolving
domains.
In the context of the application domain of precision oncology, I evaluate this hypothesis
using sets of known relationships as seeds, and attempting to generalize from them using
both attributional (which drugs are similar to the known inhibitors of x?) and relational
(which drugs relate to gene x in a similar manner to known inhibitors of x?) similarity,
with the following Specific Aims:

3

Aim 1: Develop and implement models of attributional and relational
similarity
Models of relational and attributional similarity are developed using two widely-used
distributional semantics techniques: Random Indexing (M. Sahlgren, 2005) (RI) and
Neural Word Embeddings (Mikolov, Chen, Corrado, & Dean, 2013; Mikolov, Yih, &
Zweig, 2013) (NWE).
Aim 1.1 Relational similarity.
With RI, I explicitly identify drug-gene pairs, and derive vector representations of these
concept pairs from the terms that occur between them. The similarity between the resulting
pair vectors is used to draw inference about previously unseen pairs. With NWE, I use
implicit relational information by performing geometric operations on concept vectors
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
(𝐷𝑟𝑢𝑔
𝑐𝑢𝑒 − 𝐺𝑒𝑛𝑒𝑐𝑢𝑒 + 𝐺𝑒𝑛𝑒𝑡𝑎𝑟𝑔𝑒𝑡 ≅ ? (Mikolov, Chen, et al., 2013). Relational
similarity is estimated as the cosine metric between the vector resulting from these
operations, and the NWE vector for a candidate drug.
Aim 1.2 Attributional similarity.
With both RI and NWE I use Medline abstracts as documents to build vector spaces, and
measure the cosine similarity between concepts.
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Aim 2: Recovery of held-out drug/gene relationships
Using a reference set of clinically-relevant drug/gene relationships developed for precision
oncology, the models from SA1 are evaluated for their ability to recover held-out
relationships given a set of seed examples, across a broad range of cross-validation
configurations.
Aim 3: Unsupervised identification of clinically relevant drug/gene
relationships
As implemented to meet Aim 2, relational similarity models require a set of expertgenerated “seed” examples to serve as cues. As these examples may be unavailable at the
outset of a project, in this Aim I develop and evaluate an alternative proposal in which cues
are derived without expert input, using knowledge extracted from the biomedical literature
using NLP. The attributional and relational models developed in Aim 1 are evaluated for
their performance, using a reference set of clinically-relevant drug/gene relationships.
Biomedical relevance
Although the methods developed and evaluated in this dissertation should be applicable to
identifying biomedically meaningful relationships in general, I have selected Precision
Oncology, the use of molecular characteristics of a tumor and patient attributes, to
“personalize” therapy, as an application domain on account of the pressing need for
identification of clinically relevant drug/gene relationships in this domain. (Garraway,
Verweij, Ballman, & others, 2013; Meric-Bernstam, Farhangfar, Mendelsohn, & Mills,
5

2013) To support clinical decisions, domain experts must continuously review the
published literature to develop and maintain a knowledge base of cancer-related genes, and
the agents that target these genes or their associated biological pathways. (Johnson et al.,
2015) With both the number of genes and the relevant literature growing rapidly, manual
review of the literature in search of new therapies is not scalable, and there is a pressing
need for informatics technologies to help curators more rapidly retrieve and review relevant
biomedical literature. (Johnson et al., 2015; Meric-Bernstam et al., 2013) The methods
developed and evaluated in this project can serve as an important step toward that goal.
Guide for the reader
The remainder of this dissertation proceeds as follows. Chapter 2 provides an in-depth
review of the literature on distributional semantics, relational and attributional similarity,
theoretical and cognitive basis of relational similarity, question answering, and informatics
needs of precision oncology. Chapter 3 describes the details of my preliminary
experiments, and in particular AIMED(Fathiamini et al., 2016), an application built to
retrieve drug/gene relationships from biomedical text, which elucidates some of the
challenges of this task in the domain of precision oncology, and helps form a basis for the
next experiments. Chapter 4 reports on the details and results of the Specific Aims 1, and
2 of the research. Chapter 5 discusses the results of the Specific Aim 3, and their
significance. Chapter 6 summarizes the accomplishments, contributions of the research
described in this dissertation, and future work.
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Chapter 2: Literature Review

As explained in Chapter 1, the focus of this research is on a comparative analysis of a range
of relational and attributional similarity techniques – components of the broader field of
distributional semantics – and the application domain I have selected in which to do this
evaluation is precision oncology. As part of my preliminary studies to better understand
the characteristics and informatics requirements in this field,

I created a

Question/Answering (QA) application to help a team of curators find the answers to their
questions of type “What drugs inhibit gene X?”, and maintain a knowledge base of druggene relationships. This project helped elucidate some of the unique challenges of this task
in the domain of precision oncology, and led us to realize the need for the current research.
Some of the text in this chapter is borrowed from our published paper from this project.
(Fathiamini et al., 2016)
To follow the natural progression of ideas that led to the conception of the current research,
I will present my findings from the existing literature in the following order: First I will
briefly discuss QA systems, with a focus on biomedical QA, and in particular, as it applies
to emerging domains such as precision oncology. Next, I will touch on techniques of
relationship extraction, and make a case of why methods of distributional semantics may
be particularly valuable in this domain. Finally, I will present the recent developments in
7

relational and attributional similarity methods, and explain the need for further research in
this domain.
The challenge of biomedical information retrieval
The biomedical literature often contains answers to clinicians’ clinical and research
questions, (Westbrook, Coiera, & Gosling, 2005; WESTBROOK, GOSLING, &
PSYCHD, 2004) and clinicians believe that the quality of patient care could be improved
by online search.(WESTBROOK et al., 2004) However, the answers to two-thirds of the
questions that clinicians have about their patients are either not pursued, or pursued but not
found. (Chambliss & Conley, 1996; Currie et al., 2003; Huang, Lin, & Demner-Fushman,
2006) Further analysis shows that poorly constructed queries is one of the main reasons
why the right answers cannot be found. (Demner-Fushman & Lin, 2007; Gorman &
Helfand, 1995) Besides, given the overwhelming size of the documents that are often
returned by PubMed/MEDLINE, identifying relevant citations can be difficult, and
advanced features such as Boolean combinations of MeSH terms are seldom used.(Haynes
et al., 1990; Herskovic, Tanaka, Hersh, & Bernstam, 2007) Also physicians may be
concerned about existence of answers, have time limitations, or have doubts about the
optimal search strategy.(Ely, Osheroff, Chambliss, Ebell, & Rosenbaum, 2005; Ely et al.,
2002) They spend much less time searching for an answer than would be required to find
one.(Ely et al., 1999; W. R. Hersh et al., 2002) In general, the ability of the users to find
answers to their clinical questions using Medline is low. (W. R. Hersh et al., 2002) QA
systems have been proposed as a solution to this problem.(Athenikos & Han, 2010)
8

Biomedical QA systems
Traditionally, document retrieval systems (such as PubMed) return a list of documents in
response to a user’s query. However, this requires manual review of each document. So,
QA systems that return structured knowledge (e.g., drug A targets gene B) with links to
supporting documents are a desirable alternative.(Athenikos & Han, 2010; W. R. Hersh &
SpringerLink (Online service), 2009; Voorhees, 2001) Given the rapid growth of online
literature, it has been argued that QA capabilities are among the most critical features of
future search engines.(Athenikos & Han, 2010) QA systems try to provide accurate
answers to their questions by integrating Natural Language Processing (NLP), text
summarization,

information

extraction,

and

statistical

and

knowledge-based

methods.(Demner-Fushman, Chapman, & McDonald, 2009; Hirschman & Gaizauskas,
2001) Early QA systems only relied on term based methods to generate answers. However,
due to the availability of vast amounts of biomedical information, and its crucial role in
research and applications, there was a growing need for better QA systems that could help
researchers and healthcare professionals in their search for answers to their questions.
(Athenikos & Han, 2010) As such, biomedical QA systems moved beyond the surface level
term based analysis, drawing on knowledge-based ontological resources.(Athenikos &
Han, 2010)
Knowledge-based QA systems
A wealth of knowledge resources, including ontologies, have been developed in
biomedicine over the past few decades that can be used by computers when processing
9

complex queries, and there is evidence that they are of value for QA. (Rinaldi, Dowdall, &
Schneider, 2004; Yu & Sable, n.d.; Zweigenbaum, 2003, 2009) To provide accurate
answers, most QA systems in biomedicine draw upon these curated knowledge sources
(such as the Unified Medical Language System or UMLS), and leverage the reasoning
capabilities that ensue to address issues such as ambiguity and synonymy, and also
facilitate cross document or cross knowledge-base queries using inference.(Athenikos &
Han, 2010; Lopez, Motta, Uren, & Sabou, 2007) Analysis of the TREC Genomics Track
(“TREC Genomics Track,” n.d.), which focused solely on biomedical content and was one
of the largest challenge evaluations in biomedical QA, showed that normalization of query
terms and use of the Entrez Gene thesaurus for synonym expansion, post-filtering answers,
and the option to specify answer entity types (e.g., genes, proteins, diseases, etc.) were
among the factors associated with higher performance. (W. Hersh, Cohen, Ruslen, &
Roberts, 2007; MOLDOVAN, CA, HARABAGIU, & SURDEANU, 2003; Rekapalli,
Cohen, & Hersh, 2006)
However, structured knowledge alone is not adequate to obtain state-of-the-art
performance. The majority of medical QA system use a combination of knowledge based
and statistical methods to find their answers.(Athenikos & Han, 2010) For example, CQA1.0 (Demner-Fushman & Lin, 2007) is a semantics-based medical QA system based on the
PICO framework – a guideline of evidence-based medicine (EBM), stating that
constructing a clinical question in terms of the four areas of Problem/Population,
Intervention, Comparison, and Outcome (PICO) facilitates searching for an accurate
10

answer (Richardson, Wilson, Nishikawa, & Hayward, 1994). It uses a combination of
statistical methods (including supervised machine learning) and knowledge-based
techniques (leveraging the UMLS and MetaMap (Aronson, n.d.)) to identify relevant
Medline abstracts, ranks them using a multi-step scoring system, and returns short passages
as answers. Essie (Ide, Loane, & Demner-Fushman, 2007) is a probabilistic search engine
developed at the National Library of Medicine for the ClinicalTrials.gov database, and
provide a concept-based search using UMLS-derived synonymy, document relevance
ranking using positional information (such as location in the document with regard to
different sections) of the search phrase, and query expansion using UMLS SPECIALIST
lexicon (McCray, Srinivasan, & Browne, 1994). Essie was the best performing search
engine in 2003 TREC Genomics track (SNEIDERMAN, DEMNER-FUSHMAN,
FISZMAN, IDE, & RINDFLESCH, 2007), and one of the best in 2006. (Ide et al., 2007)
SEM-BT (Hristovski, Dinevski, Kastrin, & Rindflesch, 2015) is a biomedical search engine
that implements QA as a search in a database of semantic relations, extracted from
biomedical literature by SemRep NLP system (Rindflesch & Fiszman, 2003), a natural
language processing tool developed at the National Library of Medicine. SemRep depends
upon both MetaMap (Aronson, n.d.) and knowledge encoded in the UMLS.(Bodenreider,
2004) MiPACQ (Cairns et al., 2011) is a clinical QA systems that integrates multiple
Natural Language Processing (NLP) components to achieve deep semantic understanding
of medical questions and texts. MiPACQ provides query formulation, automatic question
and candidate answer annotation, and machine learning (ML) based answer re-ranking.
AskHERMES (Cao et al., 2011) is a clinical QA system that performs semantic analysis on
11

clinical questions and outputs question-focused extractive summaries as answers. The
system indexes five types of resources: MEDLINE abstracts, PubMed Central full-text
articles, eMedicine documents, clinical guidelines and Wikipedia articles. In an experiment
three systems (SemRep, Essie, and CQA-1.0) were examined in combination, to determine
how traditional information retrieval (Pubmed search) could be improved using
knowledge-based methods in a hybrid approach to question answering. Those systems used
varying degrees of semantic knowledge, and overall, combining those methods resulted in
better system performance than that of individual systems.(SNEIDERMAN et al., 2007)
There are medical QA systems that do not employ a knowledge-based approach. MedQA
(Lee et al., 2006) for example, uses a syntactic parser for question classification, standard
IR methods for document retrieval, and syntactic and statistical techniques such as
document zone detection and clustering for answer extraction. Still, the creators of this
system recognize the need for a domain specific parser and the importance of capturing
semantic information, and the need for UMLS concepts and semantic types to help classify
questions more effectively. (Yu & Cao, 2008; Yu, Sable, & Zhu, n.d.) What these systems
have in common is reliance on domain-specific knowledge resources. This dependence is
likely to be a liability in emerging domains.
Medical QA in emerging domains
The application domain I have selected in which to evaluate the relative merits of
attributional and relational similarity is precision oncology. This task-domain is different
than those that have motivated the development of prior QA systems. Typically, medical
12

QA systems follow an EBM-based approach, and try to provide answers supported by
extensive evidence. In rapidly evolving domains such as precision oncology, the resources
found in the clinical literature are often scarce, and relation extraction systems that rely on
well-established knowledge and favor precision over recall (such as SemRep) may miss
valuable information (On average, SemRep provides a precision of around 77% across
different experiments (Kilicoglu et al., 2008), and in one study its recall was around 55%.
(Ahlers, Fiszman, Demner-Fushman, Lang, & Rindflesch, 2007)) Further, in order to
provide accurate answers, medical QA systems often draw upon manually constructed
ontologies and leverage semantic classes or domain specific typology of questions to
provide more accurate answers, or limit the size of their result sets. However, the utility of
such semantic resources is restricted to topics where the concepts and relationships have
already been defined, usually based on well-established knowledge. Due to the rapid
emergence of new knowledge in emerging domains, there is often a knowledge gap
between the newly discovered entities and relationships, and those described in existing
ontologies (in precision oncology, an example might be discovery of new drugs that are
yet to be added to existing drug ontologies). Furthermore, knowledge from both the
literature (including clinical and cancer biology) and other sources (such as clinical trials
or pharmaceutical companies) may be relevant, which presents additional challenges for
the technologies employed. For example, pharmaceutical companies do not expose their
drug annotations as structured data, and the need to extract this information from web pages
introduces additional complications and vulnerabilities to error.

13

As part of preliminary experiments to partially address this problem, we introduced the
AIMED system (Fathiamini et al., 2016) (explained in Chapter 3). In this system, I showed
that the knowledge-driven SemRep biomedical NLP system was only beneficial for finding
established drugs, whereas with investigational agents, the performance was better when
using co-occurrence counts without the use of NLP (other than for concept extraction and
normalization). However, while recall improved with the use of co-occurrence, precision
decreased since extracted relationships were no longer constrained. These results revealed
an underexplored area between the linguistic rules and semantic constraints that systems
such as SemRep impose to identify specific relationships on the one hand (thus achieving
higher precision), and the unconstrained associations defined by co-occurrence (evident by
higher recall) on the other. In the absence of established relationships as the underlying
knowledge to constrain Boolean retrieval, the co-occurrence result sets can be
overwhelmingly large. One approach to this problem involves applying relationship
extraction techniques to find only those relations that are relevant to the query. A general
overview of relationship extraction is discussed next.
Relationship extraction
There is a large body of research concerning relationship extraction (RE), and NLP
methods that can analyze text and find the relationships of interest in biomedical
domains.(Friedman, Kra, Yu, Krauthammer, & Rzhetsky, 2001; Fundel, Küffner, &
Zimmer, 2006; Kotecki & Cochran, 2002; McDonald et al., 2005; Rindflesch & Fiszman,
2003) The goal of RE is to identify a relationship between a pair of entities of specific
14

types. The relationship can be general (like any biological relationship) or specific (such
as an INHIBITS relation).(A. M. Cohen & Hersh, 2005) Biomedical RE is often considered
a sentence level problem which relies on rules or ontologies that map terms to standard
concept representations such as UMLS Concept Unique Identifiers (CUIs). Maintaining
these representations, and subsequently, building bio-medically relevant models based on
them (that need to be rebuilt for each new domain) is time consuming and requires constant
human supervision and effort.(Trevor Cohen & Widdows, 2009) Due to inaccuracies in the
NLP process in general, and RE from the biomedical literature in particular, many
biomedical knowledge bases such as PharmGKB and DrugBank are entirely based on
manual curation.(Percha & Altman, 2015) My Cancer Genome is another example of a
manually curated knowledge base that provides precision oncology related resources.(“My
Cancer Genome, Genetically Informed Cancer Medicine,” n.d.) Similarly, the Drug-Gene
Interaction database (DGIdb) is a database of potentially druggable genes aggregated from
multiple other resources including My Cancer Genome and other manually curated
databases.(Griffith et al., 2013) Another set of techniques for sentence level RE apply
machine-learning methods, avoid rules, but require annotated sentences for training. Such
annotation is time consuming and human intensive.(Kim, Ohta, Tateisi, & Tsujii, 2003)
Linguistic patterns (such as regular expressions) have been used for RE, either as
prescribed by domain experts, or automatically by generalizing patterns from training sets
and searching among sentences to find commonalities. These methods take a long time to
process text and generate results, especially with large pattern sets. (A. M. Cohen & Hersh,
2005; Hakenberg et al., 2010)
15

Distributional semantics
In contrast to sentence-level approaches, statistical methods have been applied to find
concepts that co-occur with each other more frequently than would be observed by chance.
It has been argued that this corpus-based approach provides a more robust mechanism for
finding relationships of interest, as it infers relationships from the overall distribution of
terms across an entire corpus of text, rather than from an individual assertion.(Percha &
Altman, 2015) These methods, collectively known as distributional semantics (Trevor
Cohen & Widdows, 2009; Levy, Goldberg, Dagan, & Ramat-Gan, 2015) correspond to
cognitive models of memory recall (Trevor Cohen & Widdows, 2009; Kanerva, 2010;
Landauer, Foltz, & Laham, 1998; LUND & BURGESS, n.d.), and match well to human
judgment of pairwise correlation between biomedical concepts. (McInnes & Pedersen,
2017; Pakhomov, Finley, McEwan, Wang, & Melton, 2016) They provide fast and robust
mechanisms to find relatedness and similarity between concepts and relations (Trevor
Cohen & Widdows, 2009), and have been used to identify relationships between entities.
(Lin & Pantel, 2001; Riedel, Yao, Marlin, & McCallum, 2013) These models can also
capture information concerning the nature of the relationships between terms, either
incidentally (Mikolov, Yih, et al., 2013), or by design (Turney, 2005). An important
distinction concerning the nature of the estimates derived from these models is that between
attributional and relational similarity.
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Attributional similarity
The majority of the research on distributional semantics has focused on attributional
similarity – similarity between objects or their properties. (Medin, Goldstone, & Gentner,
1990) That is to say, distributional methods have been developed and evaluated for their
ability to capture the similarity between conceptually-related entities. This is possible
because distributional methods enable the estimation of a quantitative measure of semantic
relatedness between terms from the contexts in which they occur in across a large corpus
of text. Geometric approaches to this problem involve the derivation of reduceddimensional (i.e. with dimensionality less than the number of unique contexts, or context
terms in a corpus) vector representations of terms from the contexts in which they occur
(Turney & Pantel, 2010), such that terms that occur in similar contexts will have similar
vector representations. The distance between the resulting vectors provides a meaningful
estimate of semantic similarity and relatedness. Such approaches include (but are not
limited to) Latent Semantic Analysis (LSA) (Landauer & Dumais, 1997), and the
Hyperspace Analogue to Language (HAL) (Lund & Burgess, 1996), which have been used
to find similarity between terms and documents with good correspondence with human
performance across a range of cognitive tasks. (Landauer et al., 1998; LUND &
BURGESS, n.d.) Another method, Random Indexing (M. Sahlgren, 2005) generates a
reduced dimensional space and produces similar results to LSA in evaluations of the quality
of term-term similarity such as synonym tests, and correspondence with free association
norms (Kanerva, Kristoferson, & Holst, 2000; Magnus Sahlgren, 2006), while requiring
17

much less computational power.(Trevor Cohen & Widdows, 2009; M. Sahlgren, 2005)
These methods have been applied to problems such as information retrieval (Deerwester,
Dumais, Furnas, Landauer, & Harshman, n.d.), literature-based knowledge discovery
(Gordon & Dumais, 1998), bilingual information extraction (Widdows et al., 2003), and
relationship extraction (Pedersen, Pakhomov, Patwardhan, & Chute, 2007). More recently,
neural word embeddings (Mikolov, Chen, et al., 2013; Mikolov, Yih, et al., 2013) have
become a popular method of generating such reduced-dimensional representations, with
improvements over prior distributional methods in some evaluations (Baroni, Dinu, &
Kruszewski, 2014) (although some of these improvements have been shown to be
contingent upon optimal configuration of model hyper-parameters in subsequent
experiments (Levy et al., 2015)).
Relational similarity
Relational similarity, on the other hand, involves similarity between any two given pairs
of concepts – if A’s relationship to B is similar to C’s relationship to D, then A::B is in
relational similarity to C::D. Theories of analogy seem to agree that relational similarity is
a fundamental component of analogical reasoning. (GENTNER, 1988; Medin et al., 1990;
Medin, Goldstone, & Gentner, 1993) According to those theories, similarity requires a
point of reference – one must specify the aspect from which two things are similar (e.g.
drugs can be similar based on their clinical effect, chemical composition, etc.) – and in the
case of relational similarity, the relational commonalities provide the relevant aspect of
similarity (as in “Drug A and B are similar based on their relationship to gene C”).
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(Goodman, 1972; HOLYOAK & THAGARD, 1989; Medin et al., 1993) In the section that
follows, I review some of the recent work in distributional semantics that has attempted to
estimate structural similarity of this sort from text directly.
In seminal work in this area, Turney and Littman created a Vector Space Model (VSM) for
calculating relational similarity.(Turney & Littman, 2005) Sixty-four “joining words”
(such as “for”, “of”, “to”, etc.) were used to create patterns of both “A join B” and “B join
A” (such as “A of B”, “B of A”, etc.). Then, they characterized the relationship between
two words (A and B) by counting the number of times they appeared in those patterns
across the corpus, which yielded a vector of 128 numbers for each A::B relationship of
interest. The relational similarity between any two given pairs of words was then
represented by the cosine similarity between their corresponding vectors.(Turney &
Littman, 2005) This work was then extended by Turney to develop Latent Relational
Analysis (LRA) [47], a technique for measuring relational similarity that adapts the VSM
model in three ways: 1) patterns are extracted from the corpus dynamically by finding
exemplar phrases that involve the pair of interest, 2) a thesaurus is used to extend the search
space by including words that are similar to the query terms (the pair), and 3) in a manner
reminiscent of LSA, Singular Value Decomposition (SVD) is used for dimension reduction
of the resulting pair-by-pattern matrix.(Turney, 2005) As such, LRA may be inconvenient
to implement, particularly when pairs of interest change frequently and the text corpus is
large, and may scale poorly to large sets of concept pairs on account of the need to apply
the SVD. For example, in one 2005 experiment it took LRA nine days to return results for
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374 analogy test questions, running on a matrix of 8,000 columns and 17,232 rows (48
pairs per question, with some omissions). Although the software was not optimized for
speed (Turney, 2005), and the decomposition would no doubt run faster on contemporary
hardware, decomposing a matrix with as many rows as there are concept pairs of interest
is a computationally inconvenient feature of this model.
Recent work in the general domain has attempted to estimate relational similarity from
term (rather than pair) vector representations directly, finding that word vectors derived
from a scalable neural network model can implicitly capture information of this sort.
Specifically, Mikolov and his colleagues developed two neural network architectures,
continuous bag of words (CBOW) (which learns to predict a word based on the words that
surround it), and the continuous skip-gram model (which learns to predict context words
based on an observed word). These “word embedding” architectures were used to train
word representations from large corpora (billions of words), and the resulting word vectors
were shown to capture relationships between words, which could be recovered with simple
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ −
geometric operations. For example, using the resulting vector representations, 𝑃𝑎𝑟𝑖𝑠
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ + ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝐹𝑟𝑎𝑛𝑐𝑒
𝐺𝑒𝑟𝑚𝑎𝑛𝑦 ≅ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝐵𝑒𝑟𝑙𝑖𝑛.(Mikolov, Chen, et al., 2013; Mikolov, Yih, et al., 2013)
Training of these architectures occurs through a process of online learning (ShalevShwartz, 2011), in which each training context (a “sliding window” of words surrounding
each observed word) is considered independently (though global term frequency statistics
are used to inform subsampling strategies). This permits parallel implementation of the
training process, enhancing scalability. Alternatively, it has been shown that it is possible
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to capture such relational information without training a predictive model (such as a neural
network) on an example-by-example basis. Specifically, Pennington et al. introduce Global
Vectors (GloVe (Pennington, Socher, & Manning, 2014)), a model for the unsupervised
learning of word representations that utilizes global distributional statistics directly, while
nonetheless capturing similar structural information to online neural-probabilistic methods.
In some experiments, GloVe performed better than comparable neural network approaches
in evaluations on pairwise analogies (Pennington et al., 2014), however these advantages
were not replicated in subsequent experiments in which hyperparameters and training
corpora were consistent across models (Levy et al., 2015).
Some research on relational similarity exists in the biomedical domain. Predication-based
Semantic Indexing (PSI) is a variant of Random Indexing that explicitly encodes
relationships between concepts from a collection of semantic predications (such as those
extracted by SemRep, for example docetaxel STIMULATES akt) into distributed vector
representations of these concepts.(Trevor Cohen, Schvaneveldt, & Rindflesch, 2009;
Trevor Cohen, Widdows, Schvaneveldt, Davies, & Rindflesch, 2012; Widdows & Cohen,
2015) Across several experiments (see for example (T. Cohen et al., 2014; Trevor Cohen
et al., 2012; Shang, Xu, Rindflesch, & Cohen, 2014), and for a review in (Widdows &
Cohen, 2015)), PSI was applied to infer previously unseen relationships by using relational
similarity,

including

both

harmful

and

potentially

therapeutic

drug/effect

relationships.(Trevor Cohen, Widdows, Schvaneveldt, & Rindflesch, 2011) Embedding of
Semantic Predications (ESP) is a neural-probabilistic alternative to PSI that has shown
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advantages in predictive modeling experiments using estimates of relational similarity.
(Trevor Cohen & Widdows, 2017) Both PSI and ESP use relations extracted by SemRep
rather than free text, and thus represent a different class of methods to those under
consideration in the current work.
Of particular relevance to the current work, Percha and Altman developed a method that
uses grammatical dependency paths in the sentences that contain a pair of concepts as
contextual features. (Percha & Altman, 2015) An unsupervised clustering technique called
Ensemble Biclustering for Classification (EBC) is then applied to the resulting pair-bypath matrix, such that drug-gene pairs are represented by their frequencies of co-clustering
with every other pair across large numbers of stochastically-initialized clustering
processes. As drug/gene pairs linked by similar dependency paths will cluster together,
EBC leverages relational similarity drawn from distributional statistics. Using a seed set of
ten drug-gene relationships, EBC was shown to successfully detect similar relations from
a large corpus of Medline abstracts.(Percha & Altman, 2015) The relations identified in
this process were recently made publicly available (Percha, Altman, & Wren, 2018a).
Because operates in a largely unsupervised manner, EBC is not readily adaptable to the
cue/response paradigm I employ in the current evaluation, which is limited to methods that
do not require parsing to reveal grammatical dependencies.
Summary of research on relational similarity
The techniques discussed above have been mostly applied in the general domain, resulting
in the development of online techniques, such as random projections and neural word
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embeddings, that can be used to create relational similarity models without requiring
computationally demanding techniques of dimension reduction. Given the size of the
pharmacogenomics search space, this is an important consideration. PSI and ESP are
similarly scalable, but explicitly encode relations extracted by SemRep, and therefore are
in a different methodological category to those methods attempting to infer relational
information from free text directly. Dealing with text directly is a desirable alternative in
emerging domains, on account of the time lag in the incorporation of emerging drugs into
the knowledge sources upon which NLP systems such as SemRep depend, and the fact that
SemRep’s optimization for precision over recall is not ideal for concepts that appear in a
small number of citations only. EBC searches for the relational similarity between druggene pairs by applying distributional techniques across Medline abstracts, but uses only
one type of linking relationship (dependency paths), and has not been evaluated against an
attributional counterpart. While it seems intuitive that relational similarity would be better
suited to recognition of biomedical relationships than attributional similarity, this
hypothesis has not been tested.
Overall, there is an opportunity for further research to identify techniques based on
relational similarity to identify meaningful drug/gene relationships in emerging biomedical
domains. The current research explores the application of relational and attributional
similarity techniques in precision oncology, as an exemplar of an emerging biomedical
domain, focusing specifically on drug-gene relationship extraction from Medline abstracts.
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Chapter 3: Preliminary experiments – Automatic Identification of Molecular Effects

of Drugs (AIMED)

My preliminary work examines the utility of relatively constrained semantic relationships
versus relatively unconstrained co-occurrence statistics. The results of this research
revealed an underexplored area between these two ends of the relationship extraction
spectrum, and motivated the development of a hypothesis that forms the theoretical basis
for this dissertation. The evaluation explained in this chapter was conducted in the context
of a QA system I developed to find relevant drug-gene relationships in the context of
precision oncology, which provides the practical motivation for the specific aims of this
dissertation. Some sections in this chapter are borrowed from my previously published
paper (Fathiamini et al., 2016).
Precision oncology
Precision oncology, or personalized cancer therapy, involves the use of molecular
characteristics of a tumor and patient attributes, to “personalize” therapy with the goal of
more effective and less toxic cancer treatment.(Garraway et al., 2013; Meric-Bernstam et
al., 2013) Therapy can be personalized using different aspects, including a specific
patient’s exposure history, preferences and clinical features. However, genomic profiling
is emerging as a popular personalized option that is affordable, increasingly available to
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cancer patients, and can help select “genomically-informed” targeted therapy options, and
oncologists can prescribe treatment targeted to specific molecular aberrations found in a
patient’s tumor.
To support clinical decisions, domain experts must continuously review the published
literature to develop and maintain a knowledge base of cancer-related genes, and the agents
that target these genes or their associated biological pathways.(Johnson et al., 2015)
Personalizedcancertherapy.org is one such knowledge base that can serve as a reference
for clinicians.(Johnson et al., 2015) Existing technologies that extract knowledge from the
biomedical literature are generally designed for stable domains where the state of
knowledge evolves relatively slowly. For example, one analysis found that 90% of clinical
practice guidelines were still valid at 3.6 years. (Shekelle et al., 2001) In contrast, precision
oncology evolves much more rapidly. As information concerning newer agents is relatively
scarce, established relation extraction systems that rely on established knowledge resources
and favor precision over recall (such as SemRep (Rindflesch & Fiszman, 2003), an NLP
tool developed at the National Library of Medicine) may miss valuable information.
Further, many targeted therapies are investigational and are currently available primarily
via clinical trials. Thus, there is an urgent need to develop informatics technologies to help
curate pertinent clinical information.
To this end, I developed a system for the Automated Identification of Molecular Effects of
Drugs (AIMED), which leverages semantic information extracted by the SemRep and
MetaMap (Aronson, n.d.) NLP systems, but augments this using task-specific filtering of
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results and drug-gene co-occurrence data to extract clinically relevant pharmacogenomic
relationships from the biomedical literature.
Materials
In this section I introduce the tools and materials that I have used to create AIMED.
SemRep_UTH, a modified version of SemRep
I designed and implemented a semantic QA system based on a large collection of
predications that is publicly available in SemMedDB,(Kilicoglu, Shin, Fiszman,
Rosemblat, & Rindflesch, 2012) which is generated by SemRep processing of Medline
abstracts. Semantic predications in SemMedDB are organized as Subject-Predicate-Object
triples, with subjects and objects being UMLS concepts, and predicates coming from
UMLS Semantic Network. The Semantic Network defines allowable relationship types
between any two concepts, based on their semantic type. (At, 1989) In early experiments I
realized that many of the drugs that were relevant to precision oncology were
underrepresented in this database. A search for some of these drugs (such as AZD2014) in
online versions of interactive SemRep and MetaMap (accessible at (“Interactive SemRep,”
n.d.) and (“Interactive MetaMap,” n.d.), respectively) revealed that SemRep by default uses
a rather old version of UMLS (2006), and it “suppresses” some of the short forms of drug
names, many of which relevant to my work (for example, AZD2014 was only recognizable
by MetaMap, and so SemRep, in its full form as “mTOR Kinase Inhibitor AZD2014”). To
address this problem, I updated SemRep’s data files to the latest version of the UMLS at
the time of this experiment, 2013AB. To do this, I installed UMLS locally, and modified
26

the MRCONSO.RRF file. First I identified terms with both SAB (Abbreviated Source
Name) value equal to ‘NCI’ (National Cancer Institute) and with TTY (Term Type) value
equal to ‘CCN’ (Chemical Code Name) (henceforth: NCI/CCN). For NCI/CCN terms, I
changed the ‘SUPPRESS’ value from ‘Y’ to ‘N’. This caused those terms to become
‘active’ and therefore be useable by MetaMap and SemRep. Also, for NCI/CCN terms I
changed the value of TS (Term Status) to ‘P’ (‘Preferred’) where they were ‘S’
(‘Synonym’), so that they would all be chosen by MetaMap and SemRep when
encountered. I then used MetaMap Data File Builder (“MetaMap Data File Builder,” n.d.)
to compile UMLS files and make them available to SemRep. As an additional step, I also
removed –D flag from SemRep to identify more concepts. Leaving –D in place would
block ‘dysonyms’, certain UMLS synonyms that are considered harmful. This version of
SemRep (henceforth: SemRep_UTH) was used throughout this project for extraction of
semantic predications and to normalize drug and gene names (explained below).
SemMedDB_UTH an enhanced repository of semantic predications
I used 23,537,576 PubMed abstracts downloaded in August of 2014 (henceforth:
PMAbstracts), as my knowledge source. I processed PMAbstracts (mentioned above) using
SemRep_UTH, and created SemMedDB_UTH (hosted by the NLM1) (“SemMedDB_UTH
Database Outline,” n.d.). This database is similar to the original SemMedDB in that it
follows the same database schema, but contains more predications (especially drugs and

1

https://skr3.nlm.nih.gov/SemMedDB/index_uth.html
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genes that are important for the purposes of this project), as a result of updated data files. I
also added a new table, ENTITY, which contained all the concepts recognized by SemRep
(not just the ones used to create predications). I used the information from the ENTITY
table to create co-occurrence relationships between drug-gene concept pairs at the
sentence, and document level. In a similar fashion, I used the ‘summary’ and ‘full
description’ sections from 183,260 trials downloaded from ClinicaltTrials.gov
(https://clinicaltrials.gov/) in January of 2015 (henceforth: CTDescs), and added them to
my data source. I used an original version of SemMedDB, v. 23 (Kilicoglu et al., 2012;
Rindflesch et al., 2011; “SemMedDB Info,” n.d.) as the baseline to which I compared my

results.
Drug-Gene relations reference set
To evaluate the results of my queries, I used as the reference set the gene-drug knowledge
base (henceforth: Gene Sheets) (accessible at http://personalizedcancertherapy.org, with
permission) provided and maintained by 12 cancer biologists and clinicians at the Sheikh
Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) Precision
Oncology Decision Support team at the MD Anderson Cancer Center. Each gene sheet
contained a list of drugs that are relevant for tumors with alterations in that gene. The Gene
Sheets describe genetic pathways known to be involved in certain cancer types. Each
pathway includes a main gene and a list of downstream genes that are thought to be of
interest as alternative therapeutic targets in the event the main gene cannot be directly
targeted. I used the gene PIK3CA for my formative evaluation (preliminary experiment
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below), and 17 other genes, ABL1, AKT1, ALK, BRAF, CDK4, CDK6, EGFR, ERBB2,
FGFR1, FGFR2, FLT3, KDR, KIT, PDGFRA, RET, ROS1, SMO for the summative
evaluation that followed. All the gene and drug names were normalized to UMLS concept
unique identifiers (CUIs), or Enterz Gene IDs (for genes only) using SemRep_UTH.
The Semantic Query
The semantic query was formulated to represent a query for “drugs that target genes [of
interest]”. I mapped the verb ‘target’ to different relationship types (predicates) at different
stages of my project to use in the query. In the preliminary experiment (see below), I chose
INHIBITS and INTERACTS_WITH to use in the query. The predicate ‘INHIBITS’ was
chosen because all the genes in the development and test set were oncogenes (rather than
tumor suppressor genes), and the goal was to find inhibitors of these genes. The predicate
‘INTERACTS_WITH’ was chosen by examining the existing predications from
SemMedDB_UTH, observing it tended to represent relationships pertinent to targeted
therapy. In the final stage of the project (evaluation phase, see below) I added
COEXISTS_WITH based on the insight gained from tests on a “development set” (see
below) used to find the optimal set of system parameters. The query would then involve
finding drugs (output) that were in a certain relationship (predicate) with a known list of
genes (input). The predicates were all bi-directional (with the exception of INHIBITS), so
I treated them as such, i.e. I looked for relationships in both directions. I looked for any
drug that targeted the main gene, any gene downstream, or any of their synonyms.
Downstream genes and synonyms are provided as part of the Gene Sheets. For some of
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the gene synonyms, no normalized form was found by SemRep, and they were excluded
from the analysis. I limited the query to certain semantic types. For genes, I used gngm,
aapp, enzy, and for drugs I used orch and phsu in the preliminary experiment, adding antb,
clnd, horm, imft, nnon, opco, aapp for the final stage of the project. The choice of semantic
types was made by examining the list of available semantic types in the UMLS (“Semantic
Types and Groups,” n.d.), and choosing the ones relevant to precision oncology. The choice
was eventually verified based on the results from the result from the “development phase”
(See section on “Parameter selection” below). Table 1 shows these semantic types. Figure
2 shows an overview of the system.

Table 1. Semantic types used to create co-occurrence data
Semantic Type
aapp
antb
clnd
enzy
gngm
horm
imft
nnon
opco
orch
phsu

Description
Amino Acid, Peptide, or Protein
Antibiotic
Clinical Drug
Enzyme
Gene or Genome
Hormone
Immunologic Factor
Nucleic Acid, Nucleoside, or Nucleotide
Organophosphorus Compound
Organic Chemical
Pharmacologic Substance
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Representing
Drugs and genes
Drugs
Drugs
Genes
Genes
Drugs
Drugs
Drugs
Drugs
Drugs
Drugs

Figure 2. High level summary of the AIMED system built for finding drugs that target
genes of interest.

Drug filters
The goal of this project was to find clinically-available drugs (i.e., that could be used to
treat patients). Therefore, I only retained results that were either a drug in clinical trials
(CT filter) or an FDA-approved drug (FDA filter). I downloaded the list of drugs from
FDA (http://www.fda.gov/) and normalized them using SemRep_UTH. Also, I processed
the list of drugs that were mentioned in any ClinicalTrial.gov records and normalized them
using a similar method. Furthermore, drugs available via clinical trials were associated with
the trial phase (i.e., phase 1, 1/2, 2, 3, with phase 1/2 involving both phase 1 and 2).(“The
FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective,” n.d.) For any given drug

from clinical trials, the highest phase that could be identified was used. FDA-approved
drugs were assigned phase 4. Using phase information also allowed me to limit the data
source for the query evaluation. To calculate precision and recall, each drug would be
considered within its phase category only. For example, to evaluate the query performance
for phase 3, drugs from other phases would be eliminated from the result set, and then the
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performance would be calculated against the same phase drugs from the reference set.
These constraints were motivated by the assumption that the optimal strategy to identify
drugs in each phase would depend on the number of drugs in this phase and the amount of
published literature available concerning these drugs. I also used the information from the
NCI Thesaurus (NCI filter), extracted from UMLS 2013AB, to only keep known
pharmacologic substances in a systematic fashion. With this filter, I only retained drugs
that were mentioned under the Pharmacologic Substance branch of the NCI thesaurus, as
they appeared in the UMLS.
Preliminary experiment: Comparing SemMedDB to SemMedDB_UTH
Objective
To see whether SemMedDB_UTH has any advantage over the standard version of
SemMedDB in finding drug-gene relationships
Methods
For this part of the experiment I chose one gene from the gene sheets (PIK3CA) which
included two other downstream genes (AKT, MTOR), with seven drugs that would target
the genes. PIK3CA was chosen as the starting point for the project as it was a current focus
of IPCT discussion, and a substantial amount of related literature was already available. I
ran the semantic query for this gene sheet on both databases and compared the results.
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Results
In total, the number of retrieved drugs were 74 and 35, for SemMedDB_UTH and
SemMedDB, respectively. SemMedDB_UTH showed a substantial advantage over
SemMedDB in finding drug-gene pairs for PIK3CA-related genes. (Figure 3), increasing
precision by two orders of magnitude, and identifying the remaining 70% of the reference
standard drugs that were not identified using semantic queries to the original SemMedDB.

Figure 3. Results of the preliminary experiment

Discussion
SemMedDB_UTH showed a clear advantage over the standard version of SemMedDB in
this experiment. The main difference between the two databases were in the underlying
ontology that had been used to create them. These findings underline the importance of
keeping knowledge sources up to date in this rapidly changing domain. These results also
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indicated that the changes I introduced to SemRep were in fact effective, and encouraged
me to continue my experiments.
Optimization of system parameters
Objective
During the development phase of the system, my goal was to find the best strategy for
utilizing semantic predications and co-occurrence statistics for the task of drug-gene
relationship extraction in precision oncology. Since the drugs of interest were at different
development phases, one goal was to find the best set of parameters and constraints that
would maximize query performance for each phase. I chose four genes as the “development
set” (see next section) to test the effect of different system parameters on the query
performance. The results of this development process informed the choice of parameters
for the evaluation phase.
Development Set
The development set consisted of four Gene Sheets (PIK3CA, NRAS, KRAS, MET) chosen
because they were among the first Gene Sheets developed by the IPCT, and consequently
were available for development purposes while the remainder of the reference set was
constructed. The development set also included the downstream genes in their respective
cancer-related pathways and their known synonyms, as specified in each respective Gene
Sheet. I used these four genes and their related drugs to find the best set of query parameters
and constraints that would maximize the performance.
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Parameter selection
Table 2 shows a summary of the query parameters and constraints used with the
development set, as well as the options available for each.

Table 2. Parameters of the system, as applied to query and the answers.
Parameter Name

Description

Options

Semantic
relationship

Type of relationship between drug and
gene required for retrieval.

Predications, sentence level
co-occurrence, document
level co-occurrence

Food and Drug
Administration
(FDA) filter
Clinical Trials
(CT) filter

Phase filter
National Cancer
Institute (NCI)
thesaurus filter
Frequency filter

Predication filter
Semantic type
filter for cooccurrence
Semantic type
filter for
predications

Accept drugs that appear on a list of FDA
approved drugs. The list was obtained
from fda.gov and normalized using
SemRep_UTH.
Accept drugs found in the “intervention”
field from clinicaltrials.org, normalized
using SemRep_UTH.
Accept drugs either passing the FDA filter
(marketed) or extracted from
clinicaltrials.org (CT filter) for trials with
a phase of at most x (Phases 1-3).
Return drugs that appear in the
Pharmacological Substance branch of the
NCI thesaurus hierarchy.
Minimum number of extracted
relationships (predication or cooccurrence) required before the drug is
returned.
For predications, retrieve only drugs that
occur in relationships with the target gene
of predicate type x.

Yes/No

Yes/No

Marketed, or Phase 1,1/2, 2,
3

Yes/No

One to many (e.g., 5)
INHIBITS,
INTERACTS_WITH,
COEXISTS_WITH

Semantic types of drugs to retain.

aapp, antb, clnd, horm, imft,
nnon, opco, orch, phsu

Semantic types to use with predicationbased queries

phsu, orch
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As discussed previously, the drugs that targeted the four genes in this experiment were
categorized based on their development phases (i.e., clinical trial phase 1, 1/2, 2, 3 and 4
(FDA-approved)). The phase information was validated using the latest information from
ClinicalTrials.gov. I considered precision, recall, F1 and F2 measures as my evaluation
metrics. However, published information about potentially useful drugs may be scarce and
the annotators expressed a preference for a system that would identify any potentially
useful drug. Thus, recall was more important than precision, and so, I used the F2 measure
(a variant of the F measure that emphasizes recall) as the single measure of choice to
determine the best set of parameters within each drug phase category. The F2 is calculated
as:

𝐹2 =

(1 + 22 ) ∗ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∗ 𝑅𝑒𝑐𝑎𝑙𝑙
(22 ∗ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛) + 𝑅𝑒𝑐𝑎𝑙𝑙

Exploration of the space of parameters in Table 2 in an effort to optimize the F2 metric
yielded the following parameter choices: The optimal data source for marketed (phase 4)
and phase 3 drugs was the semantic predications alone. This is not unexpected, as one
would anticipate the availability of more published literature for SemRep processing in
drugs that have advanced beyond the initial clinical trial stages. For these phases, I included
results of semantic types pharmaceutical substance (phsu) and organic chemical (orch),
retaining results for which at least 5 predication instances were found. For phases 2 and
1/2 I also included sentence level co-occurrence, and for phase 1 I used both predications
and document level co-occurrence (with co-occurrence based on the identification of
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concepts by MetaMap). Note that the set of relationships retrieved on the basis of document
level co-occurrence subsumes those retrieved using semantic predications, as document
level co-occurrence is a prerequisite to extraction of a semantic predication. The FDA filter
for marketed drugs only, CT filter for other drug phases (3, 2, 1 /2, 1), and NCIT filter for
all phases were also applied. The same set of parameters was used for Experiment 3. Table
3 shows a summary of the final set of query parameters and constraints. Table 4 shows the
actual results of the query in the development phase that informed the choice of parameters.

Table 3. Optimal system parameters and constraints determined in the development phase.
Drug Phase Source
Marketed

Predications

3

Predications

2
1/2
1

CoOcc Sen
CoOcc Sen
CoOcc Doc

Frequency Predicates
INHIBITS,
>4
INTERACTS_WITH,
COEXISTS_WITH
INHIBITS,
INTERACTS_WITH,
COEXISTS_WITH
-

Drug Semantic Type
phsu,
orch
complete list
complete list
complete list

Note: The same configuration was used for evaluation phase. Four Gene Sheets, and 115
related drugs were included in this experiment, and SemMedDB_UTH was used as the
source of semantic predications. FDA/CT, and NCI filters were applied to all phases.
CoOcc Sen: Sentence level co-occurrence, CoOcc Doc: Document level co-occurrence
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Table 4. Query results with optimal parameters for the development set.
Drug Phase
Documents
Drugs
Recall
Precision
F1
F2
Marketed
624
50
0.86
0.12
0.21 0.39
3
242
42
0.79
0.26
0.39 0.56
2
1,466
125
0.69
0.18
0.29 0.44
1/2
993
25
0.45
0.20
0.28 0.36
1
544
99
0.39
0.20
0.26 0.33
All phases
3,869
341
0.56
0.19
0.28 0.4
Note: These results informed the choice of parameters in this experiment. Four Gene
Sheets, and 115 related drugs were included, and SemMedDB_UTH was used as the
source of semantic predications.
Documents: Number of documents returned by the query. Drugs: Number of drugs
returned by the query.

Evaluate system parameters for precision oncology QA
Objective
To apply the set of parameters determined in the development phase, on a set of 17 Gene
Sheets as the “evaluation set”.
Methods and results
I used a set of 17 genes (ABL1, AKT1, ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, FGFR1,
FGFR2, FLT3, KDR, KIT, PDGFRA, RET, ROS1, SMO) as my evaluation set and
processed them using the optimal parameters determined during system development. The
gene sheets used in the development phase to identify these parameters were excluded from
this evaluation. To establish a baseline, the query was also run on the standard version of
SemMedDB using the same set of parameters. I found three- to four-fold improvements in
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recall, precision, F1 and F2 (0.39, 0.21, 0.27, 0.33 with SemMedDB_UTH over the
standard version of SemMedDB at 0.12, 0.05, 0.07, 0.09, respectively) (Table 5).

Table 5. Results of the query to find drugs from the evaluation set.

SemMedDB_UTH

DB

Drug
Phase

FDA/C
T,
Source Freq.
NCI

Predicates

Drug
ST

Doc. Drug Recall Prec.

F2

Markete
d

Yes

Pred.

>4

INHIBITS, INTERACTS_
WITH, COEXISTS_
WITH

phsu,
orch

2,251

80

0.69

0.3

0.42

0.55

3

Yes

Pred.

-

INHIBITS, INTERACTS_
WITH, COEXISTS_
WITH

-

299

61

0.35

0.3

0.32

0.34

2

Yes

-

-

205

0.5

0.17

0.25

0.36

1/2

Yes

-

-

40

0.29

0.18

0.22

0.26

1

Yes

-

-

129

0.25

0.19

0.22

0.24

12,757 515

0.39

0.21

0.27

0.33

1,730

661

0.46

0.02

0.04

0.09

1,730

661

0.17

0.01

0.02

0.04

1,730

661

0.1

0.01

0.02

0.04

1,730

661

0.04

0.002 0.004 0.01

1,730

661

0.01

0.002 0.003 0.01

1,730

661

0.12

0.05

CoOcc
Sen
CoOcc
Sen
CoOcc
Doc

complete
4,723
list
complete
3,875
list
complete
1,609
list

All Phases

SemMedDB

F1

Markete
d

No

Pred.

-

INHIBITS, INTERACTS_WITH,
COEXISTS_WITH

3

No

Pred.

-

INHIBITS, INTERACTS_WITH,
COEXISTS_WITH

2

No

Pred.

-

INHIBITS, INTERACTS_WITH,
COEXISTS_WITH

1/2

No

Pred.

-

INHIBITS, INTERACTS_WITH,
COEXISTS_WITH

1

No

Pred.

-

INHIBITS, INTERACTS_WITH,
COEXISTS_WITH

All Phases

phsu,
orch
phsu,
orch
phsu,
orch
phsu,
orch
phsu,
orch

0.07

0.09

Note: Choice of parameters from each drug phase was determined in the development
phase. In total 17 Gene Sheets with 276 related drugs were used as the reference set.
Columns: DB: database used to run the queries; FDA/CT, NCI: filters used to refine the
results; Freq.: frequency filter; Drug ST: drug semantic types; Doc: number of documents
returned; Drug: number of concepts returned by the query; Prec: precision; F1: harmonic
mean; F2: a variant of F1, emphasizing recall.

39

Error analysis
My error analysis focused on false negative results, as annotators had expressed a
preference for a system with high recall. Of all false negative results (n=168), 19% were
not found in the original knowledge sources (PMAbstracts, CTDescs). SemRep did not
identify a CUI for 24%, suggesting that they did not appear in the UMLS data files used to
extract concepts. Drug filters (CT/FDA, NCI) were responsible for 30% of the false
negative drugs. Those drugs were either absent from the source vocabularies, or their
manually designated phases were different from those specified in the filter (e.g., drug that
was in phase 1 trials at the time that the reference set was created, was in phase 2 trials at
the time of evaluation). Since all queries were phase based, the phase specified for the drug
in the reference set had to match the one specified in the CT/FDA filter, or the drug would
either be found but not matched against the reference set (wrongly marked as false positive
instead of true positive), or eliminated altogether (false negative); 23% of the missing drugs
would have been found if I had used a less restrictive approach, i.e., sentence level cooccurrence instead of predications (for phases 3 and 4), and document rather than sentence
level co-occurrence. Finally, 4% of marketed drugs were excluded by either the frequency
or semantic-type filter.

Manual evaluation
To test the hypothesis that some ostensibly false positive results were actually relevant,
three domain experts from the IPCT scientific team each reviewed 50 retrieved drugs. For
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each drug, experts were provided with a normalized concept name, targeted gene, a random
selection of up to ten source excerpts of one or more sentences, and a link to the source
document for each excerpt. To facilitate evaluation, drug and gene names were highlighted.
For document level co-occurrence results, all sentences from the original document that
contained the terms in question were provided. Drugs were picked in a stratified random
manner from a pool of 515 retrieved drugs, equally distributed across the five phase
categories (i.e., 1, 1/2, 2, 3 and marketed). Each evaluator had 40 unique drugs, and 10
drugs in common with the other evaluators to assess inter-observer agreement. Thus, a total
of 135 drugs were evaluated. Each evaluator assigned a score of 1 through 3 to each source
excerpt (Table 6).
Of the 135 drugs that were reviewed, 35 (26%) were found to receive score 3, 82 (61%)
received score 2 and 18 (13%) received score 1. Inter-observer agreement was 100%
(reviewers 1 and 2), 100% (reviewers 2 and 3) and 60% (reviewers 1 and 3). The drugs
used to assess inter-rater agreement were different for each reviewer pair. Table 7 shows a
summary of the distribution of drugs among the reviewers.
Most of the manually reviewed results were in the score 2 group, which meant that they
were relevant for review, but the level of evidence did not merit inclusion in the reference
set (Gene Sheets). The score 2 group was retrospectively divided into three subcategories
(high relevance – useful to communicate to clinicians but not recommended as therapy,
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Table 6. The scoring system that evaluator used to score the drug lists
Score
3

2

1

Description
Evidence exists to add to reference set (Gene Sheets).
Criteria:
Either:
 Drug directly targets and inhibits the gene
OR
 Drug indirectly targets the gene by inhibiting downstream pathway members
AND
there is evidence that alterations in the gene sensitize cells to drugs inhibiting the
indirect target
Gene name or its alias is mentioned with the drug or its synonym, but evidence is not
sufficient to add to reference set.
Categories:
High relevance
 Indirectly targets the gene but there is no level of evidence for its use in
tumors with alterations in the gene.
 Partial response
 Associated with resistance
 Effective only in combination
Low relevance
 Mutation negative (Patients negative for mutations in a gene were treated with
a drug)
 Opposite association (text suggests that the gene target effects the drug, not
the other way around)
 Discussing an isoform or artificial version of the gene
 Derivative of the drug is being discussed (not actual drug indicated in
evaluation)
 Association unclear
 Drug targets molecule upstream of original target (not likely to be effective)
 No effect
No relevance
 Not a drug/not used as a drug
 No relationship/Effect untested
 Drug is used as a carcinogen/ would never be used to treat cancer
 Opposite effect (The drug results in increased activity of the target gene)
Not classified
No mention of the drug and/or gene or its alias
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Table 7. The distribution of drugs among reviewers.
Drug Count
(Drug Number)
40 (1-40)
40 (41-80)
40 (81-120)
5 (121-125)

Reviewer Agreement Details

5 (126-130)

1&3

5 (131-135)

2&3

1
2
3
1&2

5/5 = 100% Both evaluator gave score 2 to all
the 5 drugs.
3/5 = 60% Both evaluators gave 3 of the drugs
score 2.
Evaluator 1 gave one drug score 2
where evaluator 2 gave it score 3.
Evaluator 1 gave another drug score
3, where evaluator 2 gave it score 2.
5/5 = 100% Both evaluators gave score 3 to 3 of
the drugs, and score 2 to the other
2.

low relevance, and no relevance), based on curator feedback. Of note, approximately 26%
of the ostensibly false positive results were in fact relevant for inclusion in the gene sheet.
If this finding were consistent across the entire evaluation set, the re-estimated precision
and recall would be 0.29 and 0.55, respectively (versus current 0.21 and 0.39, respectively).
However, I cannot exclude the possibility that there are other relevant drugs that were
neither retrieved by the system, nor recognized as such by our team of curators. In this
case, recall may be overestimated.
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Discussion
At first glance the recall, precision and F2 achieved by AIMED in the evaluation phase are
relatively modest. However, manual review of ostensibly false positive results showed that
26% were actually true positives and an additional 61% were appropriate for review, but
there was insufficient evidence to include these in the reference knowledge base. On the
one hand this finding shows that the process of maintaining such knowledge bases (which
is mostly done manually (Griffith et al., 2013; “My Cancer Genome, Genetically Informed
Cancer Medicine,” n.d.; Percha & Altman, 2015)) can benefit from automated systems. On
the other hand, it is an indication of how this field is constantly evolving (exemplified by
the progression of drugs through the development phases during the course of this work)
and no “gold standard” is likely to be complete, or remain complete for long. The
performance of a knowledge-based system depends on the accuracy and breadth of the
source knowledge.(Basili, Hansen, Paggio, Pazienza, & Zanzotto, n.d.; Hristovski et al.,
2015; Lopez et al., 2007) This is consistent with my findings, as I showed that default
predications from the original SemMedDB were only modestly useful in finding emerging
medications. Their utility was greatly enhanced by updating SemRep’s source vocabulary,
and adding predications from other knowledge sources (clinical trials). Further, we
enriched the underlying ontology by modifying the data files that SemRep was using to
include suppressed drug names from the NCI thesaurus. Although that technique helped
with some drug categories, for drugs from lower development phases we had to further
relax constraints by including co-occurrence data. Which raises the question of whether
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one could just use co-occurrence, instead of any NLP-derived relationship (i.e. predications
from SemMedDB_UTH in this case) to find the drugs of interest. My next experiment
examines this possibility.
Comparing co-occurrence data with predications
Objective
To evaluate the utility of sentence level co-occurrence data for the task of finding druggene relationships of interest. In the previous experiment, I showed that combining
predications with co-occurrence data can be beneficial, and the utility of each method
depends on how far advanced the drug is in its development phases. Drug-gene pairs that
are found in predications are always a subset of sentence level co-occurrence data, and
since SemRep favors precision over recall. So, a logical assumption might be that using all
drug/gene co-occurrence data, irrespective of whether a predication was identified or not,
would result in better recall. In this experiment, I evaluate this hypothesis.
Methods and results
For this experiment, I designed two sets of queries. In the first set, only predications were
used for all the phases, and to maximize the recall for predications, no frequency or
predicate filters were applied. In the second set, only sentence level co-occurrence was
used across all the phases. The results are presented in Table 8. Overall, the recall is 0.29
and 0.44 with predications and co-occurrence respectively, and the precision is 0.13 and
0.08 respectively.
45

Table 8. Comparing predications with co-occurrence.

Co-occurrence

Predications

DB

Drug
FDA/CT,
Phase
NCI
Marketed
Yes
3
Yes
2
Yes
1/2
Yes
1
Yes
Marketed
3
2
1/2
1

Source
Predications
Predications
Predications
Predications
Predications

All Phases
Yes
Yes
Yes
Yes
Yes
All Phases

CoOccSen
CoOccSen
CoOccSen
CoOccSen
CoOccSen

Doc

Drug

5046
389
467
413
129

True
False
Positive Negative
440
30
5
64
18
34
91
23
47
12
2
22
29
8
87

6444
35706
2614
4723
3875
1342

636
919
172
205
40
97

81
31
30
35
7
18

48260 1433

121

Recall Precision
0.86
0.35
0.33
0.08
0.08

0.07
0.28
0.25
0.17
0.28

195
4
22
35
17
77

0.29
0.89
0.58
0.5
0.29
0.19

0.13
0.03
0.17
0.17
0.18
0.19

155

0.44

0.08

Note: Drug filters were applied across both models, and not other filter was used, so that
a direct comparison could be made.

Discussion
SemRep relies on domain knowledge (UMLS) to extract relationships, by applying NLP
rules at the sentence level.(Rindflesch & Fiszman, 2003) Normally, the recall is expected
to be higher with co-occurrence than SemRep predications, since the former is not
restricted by the constraints that the latter imposes on drug-gene pairs. On the other hand,
since SemRep is optimized for precision, its results are expected to provide higher
precision than co-occurrence. My results are consistent with both of these expectations. As
we move from predications to co-occurrence data, a drop in precision, from 0.13 to 0.08 is
observed. In contrast, recall increases from 0.29 to 0.44. The increase in recall is more
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prominent in lower phase drugs than marketed drugs (0.3 for marketed drugs vs. 0.11 for
phase 1 drugs).
In the final section of this chapter I will discuss the implications of these finding, and
explain why they indicate a need for further research in this area.
Conclusion and next steps
In this chapter I introduced AIMED system that uses ontology-derived semantic relations
as well as co-occurrence statistics to find drugs that interact with genes of interest for the
purpose of supporting precision oncology. I found that relying solely on a knowledgedriven system (such as the SemRep NLP system (Rindflesch & Fiszman, 2003)) presented
us with two problems. The first problem involved an underrepresentation of oncology
drugs in the SemMedDB database (Kilicoglu et al., 2012) due to missing concepts from
the underlying ontology. To address this issue, I developed SemMedDB_UTH
(“SemMedDB_UTH Database Outline,” n.d.), which was constructed by modifying the
vocabulary used by SemRep when extracting knowledge from PubMed abstracts. While
this improved performance compared to the original edition of the database, I was still
faced with the second problem, where SemRep did not recognize some of the relationships
of interest, even when the concepts involved were already identified (SemRep relies on the
UMLS Semantic Network (At, 1989) to decide which relationships are permissible for any
given pair of concepts). To address this issue, which was more prominent in cases where
available knowledge was particularly scarce (e.g., drugs in early phase clinical trials), I
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used co-occurrence statistics to improve performance. However, recall improved, but
precision decreased, since results were no longer constrained by the underlying ontology.
These experiments revealed an underexplored area between the linguistic rules and
semantic constraints that systems such as SemRep impose on the one hand (thus achieving
higher precision), and the unconstrained relationships defined by co-occurrence (evident
by higher recall) on the other. Absence of predefined relationship types to constrain
Boolean retrieval can lead to overwhelmingly large result sets. The question arises as to
whether other mechanisms than semantic predications (or NLP-based sentence-level
relationship extraction in general) might be used to constrain the large numbers of
drug/gene co-occurrence instances detectable in the literature to identify drugs of interest.
In the following chapter I evaluate the extent to which methods of distributional semantics
can be applied to this end.
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Chapter 4: Comparing models of attributional and relational similarity for recovery

of held-out drug/gene relationships

In the previous chapter, I introduced AIMED, a QA system that tries to find relevant druggene relationships for precision oncology, by using knowledge-based NLP methods and
unconstrained co-occurrence information. I showed that NLP methods, which depend on
established knowledge, have limited coverage in rapidly evolving domains such as
precision oncology, and in particular with drugs in lower development phases (evident by
low recall). On the other hand, using co-occurrence as a means to find relationships in an
unconstrained fashion, presents us with a different problem, as the number of results
returned by the system can be too large to be useful (low precision). One potential solution
involves statistical systems that neither rely on explicit assertions (co-occurrence), nor are
limited to pre-defined relationship types (such as “INHIBITS” in the case of knowledgebased predications), and reason on the basis of similarity. In this chapter I explore the utility
of a corpus-based approach to this problem, by applying a range of relational and
attributional similarity methods, in the framework of the specific aims for my dissertation.
Much of the material presented in this chapter is borrowed from a manuscript under review
for publication at the time of this writing.
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Background
According to the “distributional hypothesis” in linguistics (Harris, 1954) words that occur
in similar contexts are likely to have similar meanings. Methods of distributional semantics
derive similar representations for terms that occur in similar contexts in the
literature.(Trevor Cohen & Widdows, 2009) Thus, two drugs that exist in similar contexts
(e.g. a document, or a sliding window) may be similar in some respects. Attributional
similarity concerns the similarity between entities (such as two drugs) (Medin et al., 1990),
which with distributional methods is estimated based on the contexts in which they occur
across a large corpus. (Landauer & Dumais, 1997; Turney, 1997) In contrast, relational
similarity concerns the similarity between pairs of entities (such as two drug-gene pairs)
(Turney & Littman, 2005), and with distributional methods is estimated from the contexts
in which these entity pairs occur together (see for example (Turney, 2005)). While it seems
intuitive that relational similarity could help to identify relationships of interest between
biomedical concepts, little was understood about the relative merits of relational and
attributional similarity as a means to accomplish this task at the outset of this doctoral work.
To address this gap in the literature, the work described in this chapter involves an
evaluation of the relative utility of relational and attributional similarity for a task of this
nature. Specifically, I compare the performance of multiple relational and attributional
similarity methods on the task of identifying drugs that may be therapeutically useful in
the context of particular molecular aberrations, compared to a gold standard (“the reference
set”) created by a team of human experts. I use known examples from the reference set as
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seeds and apply similarity measures to find target drugs in the search space. My hypothesis
is that relational similarity will be more effective than attributional similarity when applied
to this task.
In the sections that follow I will describe the steps that I took to evaluate this hypothesis. I
will provide a brief account of the construction of the search space for target drugs,
followed by a description of the reference set, and detailed account of the methods used to
estimate attributional and relational similarity.
Search space (“Training Corpus”)
I used Medline abstracts as the source of information for all similarity models in this
evaluation. Specifically, I used additional components of SemMedDB_UTH 2015
(Fathiamini et al., 2016; “SemMedDB_UTH Database Outline,” n.d.) (introduced in
chapter 3), which provides all the sentences (144M) extracted from 23.4M Medline
abstracts dated up to Sep 2014, as well as a list of the UMLS and EntrezGene concepts
found in each sentence, their semantic types, and CUIs. I replaced the narrative descriptions
of all concepts extracted by MetaMap from the abstracts with their CUIs, and removed stop
words using the stopword list from the SMART information retrieval system. (Salton,
1971) For example, “Sialyl-Tn antigen expression was studied immunohistochemically in
211

primary

advanced

gastric

carcinomas.”

was

transformed

to

“C0074480 C0185117 studied C1441616 211 C1335475”. I will refer to text so
transformed as CUI-transplanted text for the remainder of the chapter. The result of this
process was a set of 23,610,369 abstracts, with 4,288,491 unique terms, which were
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retained in an Apache Lucene index (“Apache Lucene,” n.d.) to facilitate search and
retrieval. To extract explicit drug-gene pairs and their intervening terms, I further processed
individual sentences from the CUI-transplanted abstracts, and whenever a drug co-occurred
with a gene in a sentence I extracted the words that lay between them. In this fashion, I
identified 52,465,681 drug-gene pair co-occurrence events, and combining their
intervening terms (including other CUIs and non-CUI terms) resulted in representations
for 6,899,439 unique pairs, each with a “bag of words” (BOW) consisting of every term
that occurred between their constituent CUIs in any sentence in the corpus.
Search Space Filters
Methods of distributional semantics produce continuous estimates of relatedness between
entities, and as such, they are well suited toward rank-ordering vectors within a search
space of potentially therapeutic agents. To construct this search space I removed from the
list of extracted concepts any entity that was neither a gene nor a drug. I retained only
concepts with UMLS semantic types aapp, antb, clnd, horm, imft, nnon, opco, orch, phsu
for drugs, and aapp, enzy, gngm for genes (aapp was used for both drugs and genes),
informed by results produced by different configurations of AIMED (Fathiamini et al.,
2016). Next, since the goal of the system was to find clinically relevant drugs, I used
several filters, developed during the course of the AIMED project, to eliminate concepts
that met the semantic type constraints, but were not clinically applicable. Specifically, the
NCI drug filter only includes drugs that are mentioned in the NCI terminology as a
“Pharmacologic Substance”, the CT filter includes drugs mentioned in the clinicaltrials.gov
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database, and the FDA filter includes only FDA approved drugs. The retrieved entries had
to exist in either the FDA or CT list, and the NCI filter to pass the drug filter. To ensure
that the performance of pair and entity-based models was compared across the same search
space, only drugs and genes that had representatives in both the entity-based and pair-based
spaces were retained. To meet this last constraint, a drug would need to co-occur at least
once with the gene in question. Figure 4 shows a high-level data flow diagram providing
an overview of the data sources and algorithms employed.

Figure 4. High level data flow diagram from Medline abstracts to different models.
Note: RI=Random Indexing. CUI-transplanted Medline abstracts were used to create entity and
pair representations. The drug filters were applied, and only concepts that had representatives in
both spaces were retained. The open source Semantic Vectors package (see below) was used to
create different vector models: RI Attributional (see below), RI Relational (see below),
Embeddings Relational (see below), and Embeddings Attributional (see below). Two other models,
“random”, and “frequency” (see below) where built to establish a baseline for comparison.
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The reference set
As a reference set to test the system output and validate the results, I used the knowledge
base provided and maintained by cancer biologists and clinicians at the Precision Oncology
Decision Support (PODS) team at the MD Anderson Cancer Center, Sheikh Khalifa Bin
Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), accessible with
permission at http://personalizedcancertherapy.org. Each gene and its associated drugs
(collectively known as a Gene Sheet – GS) included in this knowledgebase was deemed by
the PODS team to have treatment implications for certain cancer types. To build upon my
findings from AIMED, I used the same Gene Sheets from the “evaluation set” of AIMED
to test my hypothesis. This list included 17 genes (and some of their
synonyms/CUI/Entrez_ID variations), and 430 drugs known to target them (and 1035
synonyms/CUI variations).
All the entries in this reference set were normalized to UMLS CUIs or EntrezGene IDs for
genes, henceforth collectively referred to as CUIs in this chapter for uniformity, by
SemRep_UTH. Some of the drugs were excluded from the evaluation, either because they
were not identified as ‘drug’ by SemRep_UTH; or because they were not found in the drug
filters (explained above). Also, following the practice explained in (Chiu, Crichton,
Korhonen, & Pyysalo, 2016), if a drug had no representation in the search space, I
systematically disregarded it in the evaluation. This resulted in the GS for one gene (KIT)
being removed from the reference set, as all its drugs were eliminated in the filtering
process. Eventually, 16 genes and 163 drugs were included in the evaluation. Table 1 shows
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a list of the genes used for this purpose, and the number of therapeutically-relevant drugs
for each of them with representation in my entity-based vector spaces before and after
imposition of the constraint that only drugs co-occurring with genes in a CUI-transplanted
sentence at least once were included in the evaluation. That is to say, the current
experiments, only drugs that met the co-occurrence constraint after filtering (bottom row
of Table 9) were considered as positive examples. This co-occurrence constraint is a
prerequisite to comparison between pair- and entity-based methods. However, it greatly
constrains the number of drugs under consideration, a limitation I will subsequently
discuss. This reduction in the number of therapeutically relevant drugs that could be
considered for my experiments with the imposition of the co-occurrence constraint had a
corresponding effect on the number of drugs remaining in the search space, reducing a total
of 3,256 represented drugs (after filtering) to 1,144. The proportion of drugs that were
therapeutically relevant in at least one context was similar before (.073) and after (.087)
this filtering.
Many drugs that met the constraints for inclusion in the resulting reference set were shared
among two or more genes. That is to say, they were considered to be therapeutically active
in the presence of an aberration to multiple genes. Out of the 16 genes in this set, five had
all their drugs shared with other genes, and only one gene (SMO, targeted by only one
drug) shared no drug with the others. Figure 5 shows a summary of the drug overlap
between any given gene and the rest of the genes. An important implication of this overlap
is that sets of seed drugs (or seed drug-gene pairs) drawn from other gene sheets may, at
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times, include positive examples from the held-out gene sheet used at a particular point in
the cross-validation procedure.

SMO

Total unique drugs

ROS1

7

41 53 29 19 30 53 32 16

3

8

394 237

3

10

4

3

22 26 15 10 19 33 24 11

2

1

217 118

2

10

4

3

20 20 14 10

2

1

163 99

7

25 12

3

Sum

RET

PDGFRA

EGFR

24 14

KDR

CDK6

5

FLT3

CDK4

FGFR2

BRAF

FGFR1

ALK

Number of therapeutically
17 43
relevant drugs (TRD)
TRD found in entity-based spaces 11 23
(ri_att, emb_att, emb_rel, randvec)*
TRD-gene pairs found in pair9 21
based
spaces (ri_rel, frequency)*

Gene

ABL1

AKT1

ERBB2

Table 9. List of genes and number of drugs used as the reference set for evaluation

Note: There are fewer representations of drug-gene pairs than there are of therapeutically

relevant drugs, as some therapeutically-relevant drugs did not co-occur with the gene in
question, prohibiting the generation of a drug-gene pair representation. Sum: total
number of therapeutically-relevant drug/gene pairs. Total unique drugs: total number of
drugs that were considered therapeutically relevant in at least one context.
* A detailed description of the models is presented in the following sections

Figure 5. Reference set genes and the percentage of drugs that they share with other genes
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Search and Evaluation Process
I used known examples from the reference set as seeds and applied similarity measures to
find target drugs in the search space, and the results were compared against the reference
set. Based on the observation that in biomedicine there is often more than one correct
answer to any given analogy question (Newman-Griffis, Lai, & Fosler-Lussier, 2017), and
since distributional methods aim to prioritize results based on a continuous measure of
similarity, I used standard ranked retrieval metrics to evaluate the results. The Average
Precision is defined as:
∑𝑛𝑘=1 𝑃(𝑘)×𝐼𝑠𝑅𝑒𝑙𝑒𝑣𝑎𝑛𝑡(𝑘)
𝐴𝑃 =
𝑇𝑅
where n

= number of results returned

IsRelevant

= 1 for therapeutically-relevant drugs, otherwise 0

TR

= total number of relevant answers (whether they are returned or not)

P(k)

= precision at the point at which the kth result was returned.

I also calculated Mean Average Precision (MAP) as the arithmetic mean of the AP values.
The details and scope of the models involved in these evaluations are presented in
subsequent sections.
Aim 1: Develop and implement models of attributional and relational similarity
In Aim 1, I built models of attributional and relational similarity to test my hypothesis. I
used variants of Random Indexing (M. Sahlgren, 2005) and neural word embedding
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techniques (Mikolov, Chen, et al., 2013; Mikolov, Sutskever, Chen, Corrado, & Dean,
2013) to build my vector spaces. These operations were performed using the open source
Semantic Vectors package2 (Widdows & Cohen, n.d.; Widdows & Ferraro, 2008) which
provides implementations of both of these approaches, eliminating the possibility of
introducing bias on account of differences in pre-processing and tokenization of text
(semanticvectors, n.d.; Widdows & Cohen, n.d.; Widdows & Ferraro, 2008).
Relational similarity models
I used two approaches to model relational information. In the first, I explicitly identified
drug-gene pairs, and created vector representations for them based on the terms that lie
between them when they co-occur in my corpus of CUI-transplanted abstracts. Relational
similarity was estimated based on the similarity between these pair vectors. A disadvantage
of this approach is that all drug-gene pairs must be identified beforehand.
In contrast, in the second approach, I used the implicit relational information captured
during the course of generating neural word embeddings, and performed geometric
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
operations on the resulting concept vectors (𝐷𝑟𝑢𝑔
𝑐𝑢𝑒 − 𝐺𝑒𝑛𝑒𝑐𝑢𝑒 + 𝐺𝑒𝑛𝑒𝑡𝑎𝑟𝑔𝑒𝑡 ≅ ?, as in
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ − 𝐹𝑟𝑎𝑛𝑐𝑒
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ + ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
the example 𝑃𝑎𝑟𝑖𝑠
𝐼𝑡𝑎𝑙𝑦 ≅ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑅𝑜𝑚𝑒) (Mikolov, Chen, et al., 2013). Relational
similarity was estimated as the cosine metric between the vector resulting from these

2

https://github.com/semanticvectors/semanticvectors
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arithmetic operations and the vector for each drug in the search space (as this will be high
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
if 𝐷𝑟𝑢𝑔
𝑐𝑢𝑒 − 𝐺𝑒𝑛𝑒𝑐𝑢𝑒 ≅ 𝐷𝑟𝑢𝑔𝑡𝑎𝑟𝑔𝑒𝑡 − 𝐺𝑒𝑛𝑒𝑡𝑎𝑟𝑔𝑒𝑡 ).
Attributional similarity
To model attributional information, I used CUI-transplanted abstracts as documents to
build vector spaces, and measured the cosine similarity between concepts. Drugs known to
be effective against particular genes were used as seeds to find other drugs by assessing
their cosine similarity. In my first approach, I used Random Indexing to build the vector
space, and the second approach I used the same neural concept embeddings space from the
relational similarity experiment, but instead of using relationships, individual drugs were
used as seeds to find similar drugs.
Preliminary Experiments and Parameter Selection
Each of the methods introduced above can be executed using different sets of parameters
that could affect performance. Preliminary experiments were performed to choose the
optimal set of parameters for each model. All models used a minimum word frequency of
10. The vector dimensionality was 1000 for RI-based models (which tend to require
relatively high dimensionality), and 500 for neural embedding models (which have been
shown to perform well at relatively low dimensionalities).
Attributional similarity with Random Indexing (ri_att-RI)
In my first approach, I built a simple Random Indexing (M. Sahlgren, 2005) space. A set
of random vectors, one for each document in the corpus was generated by creating zero
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vectors of dimensionality 1000 and randomly assigning 10 of these values to either +1 or 1. The result is a set of document vectors with a high probability of being orthogonal, or
close-to-orthogonal, on account of the statistical properties of high-dimensional space (M.
Sahlgren, 2005). Term vectors were built by adding together the document vectors they
occurred in. This process can be expressed as:
⃗ = ∑ 𝑟𝑎𝑛𝑑𝑉𝑒𝑐(𝐷)
𝑇
(𝑡)∈𝐷

⃗ represents the term vector, D is a given document, t denotes a given term in the
where 𝑇
document, and randVec is the function to assign random vectors to documents.
Attributional similarity with Reflective Random Indexing (ri_att-RRI)
In this approach, a Term-based Reflective Random Indexing (TRRI) (Trevor Cohen,
Schvaneveldt, & Widdows, 2010) space was built. In TRRI, random vectors are assigned
to terms (a combination of terms and CUIs in my case), and added together to generate
document vectors for documents containing those terms, which are subsequently
normalized. Log entropy was used as the term-weighting scheme. This is the beginning of
an iterative training procedure – new term vectors are generated by adding together the
document vectors for documents in which they occur in, then the cycle can be repeated if
necessary. This provides a computationally convenient way of estimating the relatedness
between terms that do not co-occur directly together in documents, as terms that co-occur
with similar other terms will also have similar vectors. The process can be expressed as the
following sequence:
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⃗ = ∑(𝑡)∈𝐷 𝑟𝑎𝑛𝑑𝑉𝑒𝑐(𝐿𝐸(𝑡))
1. 𝐷
⃗ = ∑(𝐷⃗ {𝑡|𝑡∈𝐷}) 𝐷
⃗
2. 𝑇
Summarized as:

⃗ =
𝑇

∑

( ∑ 𝑟𝑎𝑛𝑑𝑉𝑒𝑐(𝐿𝐸(𝑡)))

⃗ {𝑡|𝑡∈𝐷}) (𝑡)∈𝐷
(𝐷

⃗ represents the document vector, D is the set of terms in each document, t denotes
where 𝐷
a given term in the document, randVec is the function to assign random vectors to terms,
⃗ is the final term vector. Ri_attLE is the log entropy term weighting function, and 𝑇
RRI was built with the same dimensionality and number of random values as the
previously discussed ri_att-RI space, over a single iteration (random term vectors 
document vectors  term vectors).
Relational similarity with pair vectors and Random Indexing (ri_rel-RI)
As a relational counterpart to ri_att-RI above, I created vector representations of
drug/gene pairs in accordance with the RI paradigm (Kanerva et al., 2000). I treated each
distinct BOW (see above) as a pseudo-document, generating pair vectors by adding
together the random vectors for the terms in each BOW and normalizing the result. No
term weighting scheme was used. This process can be expressed as:
𝑃⃗ = ∑ 𝑟𝑎𝑛𝑑𝑉𝑒𝑐(𝑡)
(𝑡)∈𝑃
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where 𝑃⃗ represents the pair (pseudo-document) vector, P is the set of terms in each BOW,
t denotes a given term in the BOW, and randVec is the function to assign random vectors
to terms.
Relational similarity with pair vectors and Reflective Random Indexing
(ri_rel-RRI)
This model was similar to ri_rel-RI in that I treated each distinct BOW as a pseudodocument, and created pair vectors by adding together vectors for terms in each BOW and
normalizing the result. The difference, however, was that instead of using random vectors
for terms, I used the term vectors trained in the process of TRRI for ri_att-RRI model
explained above. I hypothesized that doing so would provide the means to assess the
similarity between pair-based pseudo-documents containing semantically related but nonidentical terms. The process of generating pair vector representations can be expressed as:
𝑃⃗ = ∑ 𝑟𝑒𝑡_𝑎𝑡𝑡𝑟𝑖𝑏_𝑅𝑅𝐼(𝑡)
(𝑡)∈𝑃

where 𝑃⃗ represents the pair (document) vector, P is the set of terms in each BOW, t denotes
a given term in the BOW, and ret_attrib_RRI is the function responsible for retrieving term
vectors from the ri_att-RRI space.
Relational similarity with concept embeddings (emb_rel)
A second class of relational models were built using the Semantic Vectors implementation
of the Skipgram-with-Negative-Sampling (SGNS) algorithm, following the descriptions
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provided in (Mikolov, Chen, et al., 2013; Mikolov, Sutskever, et al., 2013) for word
embeddings, with the source abstracts (rather than sentences) as documents. With SGNS,
a neural network is trained to predict the terms surrounding an observed term, within a
sliding window that is moved through the text. The probability of a surrounding term given
an observed term is estimated as the sigmoid function of the scalar product between the
input weights of the observed term, and the output weights of the surrounding term. The
network is trained using stochastic gradient descent to optimize the following objective:
∑
(𝑡𝑜 ,𝑡𝑐 )∈𝐷

log 𝜎(𝐼(t o ). 𝑂(t c )) +

∑

log 𝜎(−𝐼(t o ). 𝑂(t ¬c ))

(𝑡𝑜 ,𝑡¬𝑐 )∈𝐷ʹ

where D is a set of observed terms (to) and their context terms (tc), D’ is a set of observed
terms (to) and corresponding randomly drawn terms (tc) that are unlikely to occur in the
context of the observed terms. I denotes the input weights for each term, O denotes the
output weights for each term, and  is the sigmoid function, which converts the scalar
product of the input and output weights concerned into a value between 0 and 1 that can be
interpreted probabilistically. Optimization of this objective results in high predicted
probabilities for terms that occur in the context of an observed term, and low predicted
probabilities for terms that do not. The input weights (I) are retained as the word (or
concept) embeddings, although it has been shown that retaining the output weights (O) is
advantageous in some experimental settings (Levy et al., 2015). Neural embeddings have
been shown to capture a form of implicit relational similarity, which can be used to solve
proportional analogy problems of the form “a is to b as c is to what?” (Mikolov, Yih, et
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al., 2013), using simple geometric operations. With this model, assuming drug1 has a
similar effect on gene1 to drug2’s effect on gene2, an equation can be established such
that, assuming relational information is captured accurately: ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑑𝑟𝑢𝑔1 − ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑔𝑒𝑛𝑒1 ≅ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑑𝑟𝑢𝑔2 −
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗ . In my example, drug1 and gene1 are in a known relationship with each other, and
𝑔𝑒𝑛𝑒2
the goal is to find drug2 in relationship with the gene of interest, gene2. As such, drug2
can be found using this equation:
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑑𝑟𝑢𝑔2 ≅ ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑑𝑟𝑢𝑔1 − ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑔𝑒𝑛𝑒1 + ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝑔𝑒𝑛𝑒2
Attributional similarity with concept embeddings (emb_att)
In this experiment, I used the same word embeddings space as the previous model to find
drugs similar to known drugs from the reference set.
Parameter variations with embeddings models
Prior work has evaluated the effect of neural word embedding hyper-parameters on task
performance in the biomedical domain (Chiu et al., 2016; Levy et al., 2015). I assessed two
of those parameters: subsampling (ss: the process of ignoring instances of frequently
occurring terms with some probability – I used 1 − √(𝑇/𝐹) as described in (Mikolov,
Sutskever, et al., 2013), where T is a threshold, and F is the number of times a term occurs
in the corpus divided by the total number of terms in the corpus) at thresholds of 10-3 and
10-5, and window size (ws: the number of words considered before and after the target
word, in the context of a sliding window) at levels 5 and 8. Furthermore, based on the
findings by Levy et al. (Levy et al., 2015) who showed that adding context vectors to word
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vectors (w+c) with SGNS could help improve performance on pairwise analogy tasks, I
tested models with and without context vectors. Overall, six versions of the embeddings
search space were built using different combinations of these parameters, as summarized
in Table 10.
Baseline models
To establish a baseline and to assess the effect of co-occurrence alone without any
similarity measure, the original drug-gene pairs that were identified in the course of
building the ri_rel models were sorted based on their frequency of co-occurrence across
the entire search space. In this model (henceforth: “frequency” model), the more a drug
co-occurred with a gene, the higher it ranked. For each gene of interest, the resulting ranked
list of drugs was compared with the reference set for evaluation.
A second baseline model was built using a set of random vectors for individual concepts
(henceforth: “rand-vec” model). In a manner similar to the attributional methods
described above, drug vectors were used to find similar drugs, and the results were
compared with the reference set for evaluation. The intuition here was since the vectors
used in this model were randomly chosen, they have a high probability of being orthogonal
or close-to-orthogonal to each other. Consequently, any performance observed must occur
on account of random overlap between vectors (as they are not perfectly orthogonal), or
because drugs overlap across reference sets (as discussed above). Thus, inclusion of the
rand-vec model permits us to estimate the extent to which observed performance
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exceeds that produced by incidental overlap. Table 10 summarizes different models, and
their variants, used for search.

Table 10. Similarity models used for search.

Random Indexing

Attributional

Relational

ri_att: Abstracts as documents, ri_rel: Drug-gene pairs-based BOW as
cosine
similarity
measured document, cosine similarity measured
between pair (document) vectors
between term vectors
- ri_att-RI: term vectors sum of
random document vectors (RI)
- ri_att-RRI: term vectors sum of
document vectors trained on random
term vectors (TRRI)

- ri_rel-RI: document vectors sum of random
term vectors (RI)
- ri_rel-RRI: document vectors sum of term
vectors from ri_att-RRI

Baseline

Word Embeddings

emb_att:
Abstracts
as emb_rel: Abstracts as documents, cosine
documents, cosine
similarity similarity measured after geometric
operations on term vectors:
measured between term vectors

⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝐶𝑢𝑒
𝐷𝑟𝑢𝑔 − ⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝐶𝑢𝑒 𝐺𝑒𝑛𝑒 + 𝑇𝑎𝑟𝑔𝑒𝑡
𝐺𝑒𝑛𝑒 = ?

- emb_att-001_ws5: ss=10-3, ws=5
- emb_att-001_ws8: ss=10-3, ws=8
- emb_att-00001_ws8: ss=10-5,
ws=8

- emb_rel-001_ws5: ss=10-3, ws=5
- emb_rel-001_ws8: ss=10-3, ws=8
- emb_rel-00001_ws8: ss=10-5, ws=8

- emb_att-001_ws5_w+c
- emb_att-001_ws8_w+c
- emb_att-00001_ws8_w+c

- emb_rel-00001_ws8_w+c

All three variations above with w+c
All three variations above with - emb_rel-001_ws5_w+c
- emb_rel-001_ws8_w+c
w+c




frequency: drug-gene pairs sorted by the number of occurrence in the
abstracts, search by gene returned drugs
rand-vec: Abstracts as documents, cosine similarity measured between
random term vectors
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Aim 2: Recovery of held-out drug/gene relationships
In this phase, I evaluated the models from Aim 1 for their ability to recover held-out drugs
and drug-gene pairs by using a set of seeds examples from the reference set (introduced
previously), across a range of cross-validation configurations.
Cross-validation configurations
As explained previously, both relational and attributional models require seed examples,
so that ranked retrieval of target entries can occur based on similarity to these seeds. For
attributional models the seed and target were drugs, and for relational models they were
drug-gene pairs. With the frequency model the “seed” was just the gene in question,
and I ranked the drugs that co-occurred with it based on frequency. To evaluate the pairbased models, rankings of retrieved pairs containing the reference set drugs were
considered. For the sake of uniformity, I will refer to pair-based seeds and targets, simply
as “drugs”. I conducted my evaluation both at a single GS level (InGene – all cues and
targets directly concerned the gene of interest), and across all the GSs (ExGene – the gene
of interest served as the target, where all the other genes were used as seeds). My hypothesis
was that the InGene configuration would elicit the best performance from attributional
models (as retrieved drugs would be similar to drugs that are known to be effective), while
the ExGene configuration would elicit best performance from relational models (as the
nature of the relationship between therapeutically relevant drugs and the genes they target
may be consistent across genes).
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InGene models
In the InGene model the scope of the cross validation was limited to one single GS at a
time (given knowledge of some drugs known to affect this gene, can I find others?) I used
two cross validation strategies. Both strategies are forms of leave-one-out cross-validation,
but they differ with respect to the number of drugs that are retained as seeds. With the first
strategy, known as One-As-Seed (“oas”), I took one “target” drug at a time from the
reference set and used all the other drugs individually as seeds to find it and calculate AP.
Of note, since there was only one target drug to find, the AP was equivalent to reciprocal
rank in this case. MAP for each gene was calculated by averaging the set of AP results (or
rather, reciprocal ranks) obtained in this process. For t target drugs and s seed drugs, the
number of reciprocal ranks averaged is t*s. The utility of each possible seed for retrieval
of each target is evaluated. The second strategy, known as All-But-One (“abo”), involved
using all the drugs (with vectors combined) to find a single held out drug. In this model the
cue was the normalized superposition of the vector representations of all the cues
concerned. For each gene, MAP was then calculated across this set of AP results (or more
accurately, reciprocal ranks) (one for each held-out drug). Irrespective of the number of
seed drugs, this average was calculated over t reciprocal rank results. As such, the main
difference between “oas” and “abo” was that in the former, seed drugs were used
individually to find the target drug with the results averaged later, whereas in the latter, a
cumulative seed vector was used as a cue. The motivation for this design was that in
emerging domains, a single positive result could be useful as a means to identify other
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results (as in the case where annotators have yet to begin constructing a gene sheet), and
building the basis for further discoveries – hence the oas model. On the other hand, when
information is already available (as in the case of an existing gene sheet that needs to be
maintained as new potentially useful drugs are described in the literature), one would try
to maximize the robustness of the query vector by including in it as many existing positive
answers as possible – hence the abo model. It has been shown that combining multiple
examples as cues lead to better performance on analogical reasoning experiments. (Trevor
Cohen et al., 2011; Drozd, Gladkova, & Matsuoka, 2016) As such, my hypothesis was that
in any given class of experiments, the abo models would perform better than oas.
ExGene models
In the case of ExGene model (given knowledge of drugs known to affect other genes, can
I find those affecting this one?), the oas model was implemented by first adding (and
normalizing) the vectors for individual drugs under each seed gene to form one prototypical
drug vector for each GS (one gene sheet as seed), and then using that vector to find the
drugs that target the target gene. Consequently, with t target drugs for a gene sheet, and g
other gene sheets, the MAP was calculated by averaging across g average precision results.
With ExGene, the abo model simply involved adding up the vectors for all the drugs under
all the seed genes (and normalizing them afterwards) to use as the seed. Consequently, with
t target drugs for a gene sheet, the MAP simply equaled the average precision, which was
calculated only once per target gene, irrespective of the number of other gene sheets or t.
Figure 6 shows a diagram of the cross-validation configurations. I tested the models
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described in Table 10 with these cross-validation configurations, and report the median of
MAP values for the genes in the reference set. Also, as explained previously, many genes
in the reference set had drugs that were also mentioned in other Gene Sheets. I hypothesized
that this drug overlap would affect the MAP results for ExGene models, since for those
genes, seed and target sets have drugs in common. Positive correlation between model
performance and the degree of drug overlap may explain the results. To this end, I ran a
Spearman Rank Order test to evaluate the correlation between degree of drug overlap
among genes in the reference set, and the MAP results for each gene-model combination.
Final Filtering of Result
In all of the evaluations explained above, a drug-gene co-occurrence filter was applied to
each result set from entity-based models, before calculating the AP. For each such model,
drugs that did not co-occur with the gene in question in at least one original source sentence
were eliminated, so that entity and pair-based models could be compared against the same
set of constraints.

Results
I ran some preliminary experiments to determine the best set of hyperparameters for the
models. A summary of the net effect of those hyperparameters on model performance is
presented in Table 11. Based on these findings, I chose the following model configurations
as the representatives in their respective categories: ri_att-RRI for attributional RI,
emb_att-001_ws5_w+c

for attributional embeddings, ri_rel-RI for relational RI, and
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Figure 6. Diagram of different cross validation models.
Note: 1) oas-InGene: Drugs in a Gene Sheet are used individually to find a target drug, 2)
abo-InGene: Drugs in a Gene Sheet are combined (vectors superimposed, normalized), and
used to find a target drug, 3) oas-ExGene: Gene Sheets are used individually (with drugs
within each combined), to find drugs in a target Gene Sheet, 4) abo-ExGene: Gene Sheets
are used in combination (all their drug vectors combined) to find drugs in a target Gene
Sheet. In oas models, results from individual queries are averaged (shown as “(avg)” on
the diagram) and reported as AP for the target drug(s).

emb_rel-00001_ws8_w+c

for relational embeddings.

As shown in Table 12 below, the best performing model overall was emb_rel aboExGene, followed by emb_rel oas-ExGene, ri_rel abo-ExGene, and ri_att
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Table 11. Effect of different hyperparameters on model performance.
Hyperparameter

emb_rel

emb_att

ri_rel

ri_att

Adding context to
word vectors
Subsampling threshold
from 0.001 to 0.00001
Window size from 5 to
8
Replacing RI with RRI

increase 40%
increase 21%
increase 17%
n/a

increase 25%
decrease - 3%

n/a

n/a

n/a

n/a

decrease - 2%

n/a

n/a

n/a

decrease 23%

increase - 250%

Note: Average increase/decrease is shown for each model across different configurations
(abo/oas, InGene/ExGene). Adding context to word vectors consistently improved
performance across embedding models, a finding shown in boldface. Some of the
hyperparameters resulted in a decrease in performance, shown in italics.

abo_InGene. Across RI-based models, ri_rel outperformed ri_att in the ExGene
configurations, but not in the InGene categories. With embeddings-based models,
emb_rel performed better than emb_att in ExGene models (emb_rel is not defined
with InGene). Finally, the abo configurations were associated with better performance than
oas in all models, with only one exception, ri_att oas-ExGene. The results of the
correlation test that I performed to assess a potential link between some of the results, and
the degree of drug overlap in the Gene Sheets are presented in Table 13.
A brief review of the practical utility of the methods
As discussed previously, a substantial proportion of therapeutically relevant drugs were
eliminated to facilitate comparison with pair-based models. To better estimate the practical
utility of these approaches I tested the best performing models from the relational and
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ri_rel
emb_rel
ri_att
emb_att

Attributional

Relational

rand-vec

SMO

ROS1

RET

PDGFRA

KDR

FLT3

FGFR2

FGFR1

ERBB2

EGFR

CDK6

CDK4

BRAF

ALK

AKT1

oas-InGene

0.10

0.12 0.04 0.38 0.12 0.01 0.03 0.09 0.05 0.10 0.11 0.15 0.05 0.17 0.14 1.00 0.00

abo-InGene

0.30

0.38 0.06 0.75 0.31 0.01 0.05 0.33 0.25 0.31 0.21 0.30 0.35 0.75 0.28 1.00 0.00

oas-ExGene

0.34

0.37 0.12 0.63 0.40 0.18 0.29 0.34 0.33 0.36 0.28 0.32 0.29 0.38 0.33 0.66 0.74

abo-ExGene

0.53

0.54 0.22 1.00 0.55 0.36 0.48 0.53 0.48 0.51 0.50 0.53 0.43 0.54 0.56 1.00 1.00

oas-ExGene

0.72

0.71 0.38 1.00 0.83 0.64 0.74 0.65 0.67 0.42 0.53 0.34 0.93 0.92 0.73 0.93 1.00

abo-ExGene

0.75

0.74 0.39 1.00 0.85 0.63 0.76 0.75 0.65 0.35 0.53 0.29 0.95 0.88 0.81 1.00 1.00

oas-InGene

0.16

0.20 0.09 0.53 0.23 0.27 0.38 0.11 0.09 0.09 0.14 0.14 0.08 0.20 0.52 0.17 0.00

abo-InGene

0.46

0.69 0.31 0.75 0.68 0.47 0.55 0.47 0.32 0.17 0.27 0.45 0.25 0.58 0.78 0.17 0.00

oas-ExGene

0.16

0.20 0.09 0.10 0.12 0.09 0.10 0.12 0.15 0.28 0.31 0.32 0.36 0.49 0.55 0.17 0.03

abo-ExGene

0.14

0.20 0.09 0.05 0.14 0.06 0.05 0.11 0.13 0.40 0.45 0.57 0.47 0.66 0.79 0.15 0.03

oas-InGene

0.18

0.20 0.07 0.49 0.20 0.20 0.21 0.09 0.08 0.11 0.16 0.15 0.14 0.25 0.50 0.67 0.00

abo-InGene

0.23

0.47 0.15 0.38 0.60 0.21 0.24 0.20 0.12 0.18 0.22 0.20 0.55 0.83 0.56 0.67 0.00

oas-ExGene

0.40

0.32 0.12 0.28 0.51 0.40 0.32 0.24 0.28 0.39 0.42 0.36 0.87 0.94 0.58 0.75 0.58

abo-ExGene

0.41

0.30 0.12 0.23 0.66 0.44 0.43 0.25 0.29 0.38 0.39 0.37 0.90 0.96 0.67 0.75 0.50

0.35

0.46 0.11 0.70 0.36 0.30 0.52 0.34 0.31 0.15 0.17 0.09 0.32 0.48 0.53 0.83 1.00

oas-InGene

0.02

0.02 0.01 0.03 0.04 0.01 0.00 0.01 0.02 0.02 0.04 0.03 0.03 0.12 0.14 0.00 0.00

abo-InGene

0.02

0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.02 0.04 0.01 0.07 0.23 0.28 0.00 0.00

oas-ExGene

0.15

0.18 0.03 0.12 0.12 0.07 0.08 0.06 0.08 0.23 0.26 0.24 0.27 0.39 0.49 0.19 0.03

abo-ExGene

0.27

0.45 0.03 0.21 0.23 0.18 0.14 0.06 0.09 0.69 0.59 0.73 0.60 0.73 1.00 0.31 0.03

frequency

Baseline

ABL1

Median
MAP

Table 12. MAP per gene-model combination, and the median MAP per gene.

3
20 20 14 10
7
25
*Included reference drugs 9 21 2 10 4
†Drugs with vector
3,256
representations
‡Drugs co-occurring with genes 213 797 50 231 160 183 501 302 295 141 240 177

12

3

2

1

54

24

33

76

Note: Best results for each attributional or relational method are underlined, and best
result for each gene sheet and overall are shown in boldface.
*Number of drugs in the reference set copied from Table 9.
†Drugs in the vector space after applying filters explained earlier in the text.
‡ Number of drugs available for search per gene concerned. The co-occurrence constraint
explained earlier effectively reduced the number of drugs available for search from 3,256
to 1,144 unique drugs, with an average of 217 available for consideration for each gene
(searchable drugs are shared among the genes).
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attributional categories with the full set of available drugs in the reference set (394
therapeutic applications for drugs across 16 Gene Sheets, Table 9) with all the other
constraints the same as the main experiment, and found the median MAP to drop an average
of 0.26 across those representative models (Table 14). In doing so, I am penalizing the
models for not finding drugs that are not represented in the vector space, placing a hard
ceiling on performance. It is notable that in this case, the relational models still
outperformed the attributional models, a finding consistent with those of the main
experiment.

0.72

0.55

0.51 -0.32 0.6

0.75

0.40

0.53

0.41 0.16

0.14

aboExGene

0

oasExGene

-0.03

aboExGene

-0.39 -0.32 -0.25
0.34

oasExGene

frequency

rand-vec

aboExGene

MAP

ri_att

oasExGene

Overlap/MAP Correlation -0.4

emb_att

aboExGene

Config

ri_rel

oasExGene

emb_rel

aboExGene

Model

oasExGene

Table 13. Spearman Rank-Order Correlation Coefficient values

0.63

0.35 0.15 0.27

Note: The table shows a possible link between genes with high drug overlap, and the MAP values
for ExGene configurations. The results are summarized per model. Some of the models show
high correlation between their results and the degree of overlap (e.g. rand-vec oas-ExGene and
ri_att oas-ExGene) which may help explain their higher-than-anticipated MAP. Further details
are discussed in the Discussion section. High correlation values are shown in boldface.
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Table 14. Original vs. full reference set.
Category
Relational
Relational
Attributional
Attributional
Baseline
Baseline

Model /
configuration
ri_rel aboExGene
emb_rel aboExGene
ri_att abo-InGene
emb_att aboExGene
frequency
rand-vec aboExGene

Median MAP
Original

Median MAP
Full Ref

0.53

0.25

0.75

0.34

0.46

0.15

0.41

0.16

0.35

0.16

0.27

0.15

Drop
0.28
0.41
0.31
0.25
0.19
0.12

Note: Effect of moving from using reference drugs that had representatives in the search
spaces (Original) to the full reference set irrespective of whether the target drugs were
represented in a space or not (Full Ref). Best results for attributional or relational categories
are underlined, and best result overall is shown in boldface. On average the median MAP
drops by 0.26. Only the results for best performing models in each category are shown.

Discussion
My main hypothesis was that relational similarity would be more effective than
attributional similarity in finding drugs that interact with particular genes. To this end, for
each category of relational similarity, I also developed an attributional counterpart. The
results indicate that models based on relational similarity generally outperform models
based on attributional similarity on this task, providing strong support for the utility of
analogical reasoning (exemplified by relational similarity) in the task of identifying
clinically relevant relationships in natural language text.
A related hypothesis was that ExGene configurations would be advantageous for relational
models, whereas attributional models may perform best with InGene. This hypothesis was
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supported in part by the results, as the Random Indexing based relational model exhibited
its best performance in ExGene settings, leveraging relationships involving other genes (I
did not compare relational embedding techniques for InGene configurations, as the
emb_rel model is only defined for ExGene). However, I also anticipated that attributional
models would perform worse in ExGene settings (where cue drugs interact with other genes
than the target gene). This was exemplified by the ri_att model, with a performance
drop from a MAP of 0.46 in abo-InGene to 0.14 in abo-ExGene. However, emb_att
surprisingly displayed the opposite behavior, where its performance improved upon
moving from InGene to ExGene (0.23 to 0.41). This paradoxical behavior may be due to
the fact that in many cases the genes may be functionally related to one another, a
hypothesis that is further supported by the drug overlap among Gene Sheets explained
previously. Further investigation is needed to fully explain this phenomenon, as it is not
clear why this would occur with one attributional model, but not the other.
A third hypothesis was that abo models would generally perform better than their oas
counterparts. This hypothesis held true across the majority of the experiments (with one
exception, ri_att oas-ExGene), suggesting that in emerging domains, where existing
knowledge is limited, the best strategy for creating robust query vectors may be to use as
many existing positive cues as possible. This finding is consistent with previous work on
analogical reasoning using distributed representations of semantic predications (“concept
relation concept” triples) extracted from the biomedical literature using SemRep (Trevor
Cohen et al., 2011), as well as by subsequent work on analogical retrieval in the general
76

domain (Drozd et al., 2016). As more positive examples are found, their addition to an
existing query vector will progressively add to the robustness of the query.
Regarding the nature of the underlying representation, the emb_rel model consistently
outperformed ri_rel both in oas and abo configurations. The emb_att model,
however, was only marginally better than ri_att with oas-InGene, and in the case of
abo-InGene, it fell short of this simpler model. This apparent disadvantage might be due to
the context size for the two models. While the ri_att model used the whole Medline
abstract, emb_att only used a small sliding window, which provides a limited scope, and
may help explain the poor performance. Further research is needed to test this hypothesis,
perhaps by providing a larger window for the neural embedding model, or adapting it to
treat entire documents as contextual units.
Another advantage of the emb_rel model over ri_rel was ease of generation,
efficiency, and scalability. Embedding models represent individual concepts as vectors. To
create the ri_rel search space, I had to first find and extract explicit drug-gene pairs
from individual sentences, and then create bags-of-words from their intervening terms, a
computationally demanding pre-processing step that took considerable effort to develop,
and must be repeated whenever new information is added to the corpus. Furthermore, the
resulting vector space is larger as each pair, rather than each entity, must be represented
with a unique vector. Given both the level of development, execution effort, and overall
performance, the concept-level emb_rel model offers clear advantages for relational
retrieval.
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A surprising finding amongst the results was the performance of the random vector based
baseline model (rand-vec). I expected negligible performance, as random vectors are by
design generated with a high probability of being mutually orthogonal or close-toorthogonal, and as such are not meaningfully similar to one another. While I obtained the
expected results with InGene models, those for ExGene were surprisingly productive,
particularly the median MAP of 0.27 for abo-ExGene. I believe this phenomenon is
explained by the overlap between drugs across gene sheets, providing the model with same
vector both as a seed and as target. This theory is supported by the fact that using the
rand-vec model, I obtained better results with genes that shared many drugs with other
genes than those which did not (e.g., FGFR1, FGFR2, FLT3, KDR, PDGFRA, RET). As
shown in Table 13, there is a high correlation between drug overlap and rand-vec results
in the ExGene category, 0.6 and 0.63 for oas-ExGene and abo-ExGene, respectively. The
other baseline model was frequency, which I compared to the relational models. While
with a median MAP of 0.35, the frequency model seems relatively strong in terms of
its ability to find gene-related drugs, it outperforms neither ri_rel, nor emb_rel,
indicating that these models are more effective than a simple count of co-occurrence in
finding the desired relationships.
Comparison with existing work
The results are not directly comparable to prior work in different domains. The literature
is relatively sparse on the application of neural concept embeddings in precision oncology,
or even biomedicine, as compared with the general domain. In particular, I am aware of
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only one paper in the biomedical domain that concerns using neural word embeddings
derived from unstructured text (as opposed to neural embeddings derived from semantic
predications (Trevor Cohen & Widdows, 2017)) for analogical retrieval (Newman-Griffis
et al., 2017), and this work does not compare attributional and relational models. As
mentioned previously, EBC provides an alternative method to ri_rel for estimating
relational similarity, however it is not directly comparable to my work, since my corpus
has not been parsed for grammatical dependencies. Future work, however, includes parsing
the corpus to find those dependency paths (or leveraging the set provided by the creators
of EBC (Percha, Altman, & Wren, 2018b)) so that EBC can be used. As an attributional
counterpart to EBC, Levy and Goldberg’s dependency based embeddings (Levy &
Goldberg, 2014) can be considered.
Another factor that complicates direct comparison with existing work involves exploration
of the space of model hyperparameters, which often resulted in improved performance.
Levy et al. provide an extensive description of the set of SGNS hyper-parameters that can
be altered to improve the embedding results (Levy et al., 2015). Among the many
parameters they explain, I chose to examine three – window size, sub-sampling threshold,
and adding context vectors to word vectors. In line with previous work, I found that adding
context vectors to word vectors consistently improved word embedding results (across all
the cross validation configurations) (Levy et al., 2015). Future work involves performing
a more comprehensive experiment to determine the effect of these and other parameters.
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Limitations
I faced two problems when dealing with drug-gene relationships in precision oncology.
The first problem concerned term to concept mapping (performed by MetaMap), and the
other had to do with finding relationships of interest. In the current project, I specifically
focused on the latter to fulfil the primary goal of this research – comparative evaluation of
different similarity models. Some drugs (119 out of 237 or 50%, Table 1) in the reference
set were excluded from evaluation, either because they had no representative in vector
space (e.g. because they were not mapped to CUIs by MetaMap,), or because they did not
pass the drug filters that I used (which were also based on CUIs). An additional 19 drugs
were excluded because of the co-occurrence filter. As such, some true positive results that
would have been missed were excluded to allow a “fair” comparison of models.
However, to estimate practical utility, the full reference set should be used. As shown in
Table 14, penalizing the models for missing drugs that they do not represent results in a
substantial drop in performance. More work is needed to address the limited coverage of
therapeutically relevant agents, an issue I hope to address by replacing the concept
extraction component of the system in the future. This may involve further expansion of
MetaMap vocabularies, or substitution of an alternative method for the recognition of drug
and gene entities that is not dependent on curated knowledge resources, which would be
advantageous in emerging domains such as precision oncology.
In addition, both the literature and the reference set used in this research were around 2-3
years old. Emerging domains by definition evolve at a rapid pace, and so should the search
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spaces and reference sets used in information retrieval research projects in these domains
if the resulting systems are to be practically useful.
Furthermore, while I tried to follow the current literature in selecting model hyperparameters, the current work should not be considered an exhaustive test of these
parameters. It is quite possible that other adjustments could further improve performance.
Up to this point, I tested my assumptions and techniques using cross validation across a set
constructed by a single team of PODS curators. So, the methods have not been tested in
other contexts or for similar tasks. However, the PODS curators constructed the reference
standard independently of the computational work and the main goal of this research was
to compare different similarity methods and paradigms. In the next chapter I use seed drugs
produced by NLP, to test the methods when used with an independent set of cues. This is
an important step in terms of evaluating the utility of the developed methods when applied
in a more practical scenario.
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Chapter 5: Unsupervised identification of clinically relevant drug/gene relationships

In the previous chapter, I compared the utility of a broad range of relational and
attributional models for the task of finding relevant drug-gene relationships. In those
experiments, both the “seeds” and the held out “answers” came from the same expertcurated reference set. While this type of cross validation can serve to demonstrate the utility
of the developed models, it can only be used in cases where some positive cues are already
known to the system. In practice, this may not always be feasible. In this chapter I use cues
that are extracted automatically from biomedical literature, using NLP, and evaluate the
performance of attributional and relational models developed in Aim 1.
Methods
I used SemMedDB_UTH and isolated predications that were associated with the target
genes in the reference set. I chose predications with predicate types 'INHIBITS',
'INTERACTS_WITH', 'COEXISTS_WITH' that had any of the target genes as “subject”,
and any drug (concepts with UMLS semantic types aapp, antb, clnd, horm, imft, nnon,
opco, orch, phsu) as “object”. Table 15 shows the number of predications found for each
target gene in this manner.
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RET

ROS1

SMO

KIT

KDR

FLT3

FGFR2

FGFR1

ERBB2

EGFR

CDK6

CDK4

74

BRAF

21

ALK

89

AKT1

Pred.
299 1,992 116 329 319 286 1,124 778 328 299 289 256 184 87
Count

Gene

ABL1

PDGFRA

Table 15. Predications found for each target gene.

It must be noted that the predications are not unique to Gene Sheets, as different genes may
share certain characteristics, and the same drug may target more than one gene. This is
similar to the reference drug overlap phenomenon discussed in the previous chapter, where
the unexpectedly high performance of some models (such as rand-vec) seemed to be
associated with the overlap. Similarly, assertions that are repeated in the context of more
than one gene may have a better chance of being accurately extracted.
Next, I tested the best performing models from the relational and attributional categories
from Aim 2 with these predications as seeds, and with all the other constraints the same as
the main experiment.
Configurations
Unlike the models explained in Aim 2 where seeds and targets came from the same
reference set, in this experiment the seeds (predications from SemMedDB_UTH) were
from a different set than the reference set. Therefore, cross-validation (abo or oas) was
neither defined, nor required, as the predications were used as seeds (known as
Predications-As-Seed, “pas”) to find the targets. Arguably though, the pas model is more
similar to abo than oas, since in pas, one cumulative seed vector, the sum of vectors for all
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the predications concerned, is used as cue to find one drug in a single Gene Sheet at a time
(InGene), or all the drugs in one Gene Sheet (ExGene).
Results
The results are summarized in Table 16. The best performing model in this experiment was
embeddings relational model (MAP of 0.64), followed by the RI-based relational model
(MAP of 0.31). Both the relational models outperformed their attributional counterparts.
An important question concerned how these pas models would compare against their abo

SMO

ROS1

RET

PDGFRA

KDR

0.12 8

FLT3

rand-vec
pas-ExGene

FGFR2

0.35 4

FGFR1

emb_att
pas-ExGene

ERBB2

0.03 3

EGFR

ri_att
pas-ExGene

CDK6

0.64 3

CDK4

emb_rel
pas-ExGene

BRAF

0.31 9

ALK

ri_rel
pas-ExGene

AKT1

Predications
As Seed (PAS)

Median
MAP
ABL1

Baseline Attributional

Relational

Table 16. Predications used as seeds

0.3 0.1 0.7 0.1 0.0 0.1 0.1 0.3 0.2 0.2 0.3 0.3 0.5 0.6 0.6 0.3
2 5 8 9 7 6 2 9 5 0 3 1 3 1 3
0.5 0.3 1.0 0.6 0.5 0.5 0.7 0.6 0.2 0.4 0.3 0.8 0.9 0.8 1.0 1.0
2 0 8 7 9 0 0 9 9 2 7 2 1 0 0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0
3 3 3 2 2 3 6 4 5 3 0 5 6 5 1
0.2 0.1 0.1 0.3 0.3 0.1 0.2 0.2 0.3 0.4 0.2 0.9 0.9 0.6 0.6 0.5
1 3 9 3 9 1 8 7 3 5 2 4 7 4 0
0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.1 0.0 0.1 0.1 0.2 0.3 0.2 0.1 0.0
4 8 4 8 6 5 8 7 0 4 2 8 7 3 2

Note: With predications used as seeds, MAP per gene-model combination, and the
median MAP per model across all the genes are shown. Best results for attributional or
relational categories are underlined, and best result for each gene sheet and overall are
shown in boldface. Other system parameters including the total number of drugs in the
vector space, and the number of drugs in the reference set are identical to the main
experiment from Aim 2. This experiment was only run for the best performing models in
each category from Aim 2.
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counterparts from the cross-validation experiment in Aim 2. The answer to this question
could help elucidate the role of NLP (versus human experts) as the provider of cues in this
task (although curation of the results would still require human input). As summarized in
Table 17, the median MAP dropped an average of 0.13 across the five models when moving
from abo to pas.

Table 17. Comparing pas models with their abo counterparts

ri_rel ExGene

Median
MAP abo
0.53

Median MAP
pas
0.31

Relational

emb_rel ExGene

0.75

0.64

0.11

Attributiona
l

ri_att ExGene

0.14

0.03

0.11

Attributiona
l

emb_att ExGene

0.41

0.35

0.06

Baseline

rand-vec ExGene

0.27

0.12

0.15

Category

Model / configuration

Relational

Drop
0.22

Practical utility of the methods with predications as seeds
I tested the models with the full set of available drugs in the reference set (394 therapeutic
applications for drugs across 16 Gene Sheets, Table 9) with all the other constraints the
same as the main experiment. In this case, on average the median MAP dropped by 0.17
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across the five models (Table 18). The relational models still outperformed the attributional
models, a finding consistent with those of the main experiment.

Table 18. Full reference set (Full Ref) versus the original configuration.

ri_rel pas-ExGene

Median MAP
Original
0.31

Median MAP
Full Ref
0.12

Relational

emb_rel pas-ExGene

0.64

0.27

0.37

Attributiona
l

ri_att pas-ExGene

0.03

0.01

0.02

Attributiona
l

emb_att pas-ExGene

0.35

0.16

0.19

Baseline

rand-vec pas-ExGene

0.12

0.05

0.07

Category

Model / configuration

Relational

Drop
0.19

Note: Best results for attributional or relational categories are underlined, and best result
overall is shown in boldface.

Summary of the findings
Table 19 summarizes the findings across all the experiments in this chapter. As discussed,
the best performing model overall was Relational Embeddings (emb_rel) across the four
categories of experiments.
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Table 19. Summary of the overall findings.
Controlled Reference Set
- 16 Genes
- 163 Drugs
- shared by search spaces
- limited to co-occurrence

Full Reference Set
- 16 Genes
- 394 Drugs
- all drugs

Supervised: Within Reference Set
Relational embeddings: 0.75

Relational embeddings: 0.34

(abo-ExGene)

(abo-ExGene)

Best attributional

ri_att: 0.46
(abo-InGene)

emb_att: 0.16
(abo_ExGene)

Random baseline

0.27

0.15

Best model

Unsupervised: Predications as Seed
Relational embeddings: 0.64

Relational embeddings: 0.27

(pas-ExGene)

(pas-ExGene)

Best attributional

emb_att: 0.35
(pas-ExGene)

emb_att: 0.16
(pas-ExGene)

Random baseline

0.12

0.05

Best model

Note: Relational embeddings model outperformed both the RI-based relational models
(not shown), and the attributional models. The median MAP values are presented for
each model.

Discussion
In this chapter, I showed that using the developed methods in an unsupervised manner still
produces results that are consistent with my main hypothesis. On the other hand, when
testing with the full reference set, the best performing model in this approach had a clear
advantage over the randomly created baseline (MAP of 0.27 vs. 0.05 for the random
model). This can be important from a practical perspective, since it is an indication of the
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relative utility of the methods for this task. The practical utility becomes more important
when dealing with a new domain where there is little prior knowledge available. Using the
system in those scenarios will provide the curators with some initial cues that will then help
build upon them to expand their search, and find more answers in an iterative fashion.
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Chapter 6: Contributions, conclusion, and future direction

In the work described in this dissertation, I compared relational and attributional similarity
measures for their utility in finding clinically relevant drug/gene relationships in the
context of precision oncology, which presents unique challenges on account of the pace of
evolution of clinically actionable knowledge. I found that models based on relational
similarity outperformed models based on attributional similarity on this task. This finding
consistently held true in multiple experiments across the two large paradigms of
distributional semantic methods, Random Indexing (RI) (M. Sahlgren, 2005), and neural
word embeddings (NWE) (Mikolov, Chen, et al., 2013). This is the first time methods of
relational and attributional similarity have been systematically compared in this manner,
and as the methods can be applied to identify any sort of relationship for which cue pairs
exist, my results suggest that relational similarity may be a fruitful approach to apply to
other biomedical problems. Furthermore, I found models based on NWE to be particularly
useful for this task, given their higher performance than RI-based models, and significantly
less computational effort needed to create them.
In my preliminary work, I developed the AIMED system (Fathiamini et al., 2016) to find
relevant drug-gene relationships for precision oncology, using NLP and sentence based cooccurrence. AIMED showed promising results, but it also revealed some of the
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shortcomings of knowledge based NLP methods and co-occurrence statistics, especially
with early stage drugs, which provided the practical motivation for this dissertation. The
current research takes an important step toward a better AIMED application, by providing
it with more robust alternative techniques that can potentially address some of its
shortcomings.
In the section that follows I will proceed to reevaluate my main hypothesis in the light of
the research findings I have documented in the preceding chapters.
Assessment of hypotheses
My main hypothesis was that measures of relational similarity would be of greater utility
than attributional similarity for the task of identifying biological relationships that may
answer clinical questions in the context of rapidly changing domains. My results provide
strong support in favor of this hypothesis, with estimates of relational similarity yielding
better performance than comparable measures of attributional similarity across multiple
experiments.
Additionally, during the course of these experiments, I developed other hypotheses that
were closely related to the main hypothesis. I found out that the best strategy to maximize
the robustness of a similarity-based query across a large vector space was to add vector
representations of as many cues as possible to construct a query vector. This finding was
supported by the observation that my abo models (in which all the existing cues would
form one cumulative vector to find one held out answer) outperformed my oas models
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(where cues consisted of only one cue). This finding is consistent with prior research both
in the biomedical (Trevor Cohen et al., 2011), and the general domain (Drozd et al., 2016).
A related hypothesis with potential practical implications for search in domains with
emerging knowledge is that when looking for drugs that target a gene, using information
about the relationships involving other genes as cues helps improve the accuracy of system
responses in relational models. In fact, relational models actually performed better with
cues concerning other genes, than with cues derived from held-out components of the gene
sheet under evaluation. This hypothesis was supported by the results showing that the
ExGene configurations consistently outperformed the InGene settings, when used with
relational models. From a practical point of view, this finding means that prior knowledge
of drug-gene relationships in general can facilitate the search of drugs targeting a gene of
interest. Thus, relational models have more information to draw upon than attributional
models, and the search for drugs targeting a specific gene can proceed without the need for
an agent that is already known to be effective to serve as an exemplar.
Theoretical Contribution
Similarity is a fundamental cognitive construct. (Medin et al., 1990) Similar concepts are
thought to belong to the same conceptual category in the human mind (Medin et al., 1993),
new concepts are thought to be assigned to existing categories based on how similar they
are to concepts exemplifying these categories, and evidence suggests that memory relies
on similarity operations to retrieve concepts. (Medin et al., 1993) In my experiments, I
evaluated methods that leverage mechanisms of analogical retrieval to elicit relational
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similarity. This is consistent with cognitive theories of analogy, which suggest that
relational similarity is the most important aspect of similarity for analogy processing and
retrieval.(HOLYOAK & THAGARD, 1989; Medin et al., 1990, 1993) My results indicate
that models based on relational similarity generally outperform models based on
attributional similarity in the task of identifying clinically relevant relationships in natural
language text, providing strong support for the utility of analogical reasoning for this task.
In other words, my work shows that the same mechanisms that have been proposed to
explain experimental data on analogical retrieval can also be leveraged for practical tasks
in the biomedical domain.
Informatics Contribution
This research compares methods of relational and attributional similarity, using methods
of distributional semantics (Trevor Cohen & Widdows, 2009) when applied to finding
desired relationships in emerging biomedical domains, and specifically, precision
oncology. I used techniques of Random Indexing (M. Sahlgren, 2005) and neural word
embeddings (NWE) (Mikolov, Chen, et al., 2013), and was able to establish the latter as
the technique of choice for this task across multiple experiments. To the best of my
knowledge, the relative utility of relational and attributional similarity for tasks of this
nature has not been systematically evaluated in biomedicine previously. Moreover, the
utility of NWE-based relational similarity in finding concept pairs using exemplar cue pairs
has not been explored in the context of emerging biomedical knowledge in general, and
precision oncology in particular.
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Practical Contribution
The results of this research can guide the design and implementation of biomedical
question answering and other relationship extraction applications for precision medicine,
precision oncology and other similar domains, where there is rapid emergence of novel
knowledge. The methods developed and evaluated in this project can help NLP
applications provide more accurate results by leveraging corpus based methods that are by
design scalable and robust.
Precision oncology is rapidly evolving and scientists at cancer centers spend a significant
amount of time and effort maintaining knowledge bases that directly affect clinical decision
making processes.(Meric-Bernstam et al., 2013) As a preliminary step to this research, the
AIMED project showed promising results in terms of helping expert curators find some of
their desired answers in the literature. At the same time, AIMED also revealed some of the
shortcomings of the Boolean retrieval system leveraging semantic constraints and cooccurrence frequency. The results of the current research are based on ranked retrieval by
distributional techniques, and so, they are not directly comparable to the Boolean system
of AIMED. Nonetheless, they elucidate the ways in which the applied models and
configurations can be optimized to accommodate the unique characteristics of the problem
domain of precision oncology.
In my final experiments in this project, I developed and evaluated a method in which cues
were provided by NLP methods, without human intervention. This has important practical
implications, as a data pipeline can be envisioned in which the initial selection and filtering
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of relevant information from the literature is automated, which allows human experts to
focus only on the information that has already been filtered, potentially saving time and
effort.
It must be noted that the intended users for this system are annotators rather than clinicians.
While the methods developed in the research have shown promising results, they are not
yet at a level that can be used for direct clinical decision support without human
supervision.
Future Steps
Future steps involve finding ways to improve the accuracy of my methods, test in other
domains, and find ways to increase its practical usefulness.
There is great room for improvement in terms of increasing the accuracy of the results by
developing methods that can incorporate more knowledge sources (like clinical trials,
commercial drug company web sites, drug pipelines, etc.) to increase the breadth of
available information. Both my preliminary work (AIMED) and the main research relied
on ontology based named entity recognition (NER), using MetaMap (Aronson, n.d.). This
approach posed limitations in terms of the breadth of the supported vocabulary, and as
such, application of more accurate NER technology that is already available (Leaman &
Gonzalez, 2008; Leser & Hakenberg, 2005) is a priority. Exploring other informatics
approaches to build the search space, such as using dependency paths (as explained in the
work by Percha (Percha & Altman, 2015)) to define relationships is another area of future
research. A more comprehensive experiment is needed to determine the optimal set of
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search space parameters, to accommodate the unique characteristics of rapidly evolving
domains. The methods discussed in this dissertation have only been applied to the domain
of precision oncology. Future work involves testing the techniques in similar domain where
knowledge is rapidly evolving. To increase the practical usefulness of the system, the
development of an interface to permit users to adjust query constraints in accordance with
their preferences concerning workload and completeness, is an important step toward
improving the system usability.
Conclusion
In this research, I compared relational to attributional measures of similarity across a range
of representational approaches, for their ability to recover therapeutically important druggene relationships. Relational similarity performed better than attributional similarity for
this task, demonstrating its utility as a means to identify clinically important biomedical
relationships. These results have implications for the application domain of precision
oncology, as they provide validation for methods that identify clinically-relevant drug/gene
relationships. Furthermore, these methods should be applicable to the identification of
biomedical relationships of any type where exemplar cues are available to seed the
analogical retrieval process.
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